{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:19:01Z","timestamp":1793636341391,"version":"4.5.1"},"reference-count":306,"publisher":"Bentham Science Publishers Ltd.","issue":"18","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2019,10,9]]},"abstract":"<jats:sec><jats:title\/><jats:p>Acquired Immunodeficiency Syndrome (AIDS) is a chronic disease characterized by multiple life-threatening illnesses caused by a retro-virus, Human Immunodeficiency Virus (HIV). HIV infection slowly destroys the immune system and increases the risk of various other infections and diseases. Although, there is no immediate cure for HIV infection\/AIDS, several drugs targeting various cruxes of HIV infection are used to slow down the progress of the disease and to boost the immune system. One of the key therapeutic strategies is Highly Active Antiretroviral Therapy (HAART) or &amp;#039; AIDS cocktail&amp;#039; in a general sense, which is a customized combination of anti-retroviral drugs designed to combat the HIV infection. Since HAART\u2019s inception in 1995, this treatment was found to be effective in improving the life expectancy of HIV patients over two decades. Among various classes of HAART treatment regimen, Protease Inhibitors (PIs) are known to be widely used as a major component and found to be effective in treating HIV infection\/AIDS. For the past several years, a variety of protease inhibitors have been reported. This review outlines the drug design strategies of PIs, chemical and pharmacological characteristics of some mechanism-based inhibitors, summarizes the recent developments in small molecule based drug discovery with HIV protease as a drug target. Further discussed are the pharmacology, PI drug resistance on HIV PR, adverse effects of HIV PIs and challenges\/impediments in the successful application of HIV PIs as an important class of drugs in HAART regimen for the effective treatment of AIDS.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1568026619666190619115243","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T07:21:59Z","timestamp":1561533719000},"page":"1571-1598","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Protease Inhibitors for the Treatment of HIV\/AIDS: Recent Advances and Future Challenges"],"prefix":"10.2174","volume":"19","author":[{"given":"Chandrashekhar","family":"Voshavar","sequence":"first","affiliation":[{"name":"College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","year":"2018","unstructured":"Global HIV"},{"key":"ref=2","unstructured":"Centers for Disease Control and Prevention (CDC). HIV surveillance report: Diagnoses of HIV Infection in the United States and dependent areas. (Accessed 2017)."},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1126\/science.6200936","volume":"224","author":"Gallo R.C.","year":"1984","unstructured":"Gallo R.C.; Salahuddin S.Z.; Popovic M.; Shearer G.M.; Kaplan M.; Haynes B.F.; Palker T.J.; Redfield R.; Oleske J.; Safai B.; Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984,224(4648),500-503","journal-title":"Science"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1126\/science.6206563","volume":"225","author":"Levy J.A.","year":"1984","unstructured":"Levy J.A.; Hoffman A.D.; Kramer S.M.; Landis J.A.; Shimabukuro J.M.; Oshiro L.S.; Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 1984,225(4664),840-842","journal-title":"Science"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"773","DOI":"10.4049\/jimmunol.142.3.773","volume":"142","author":"Gowda S.D.","year":"1989","unstructured":"Gowda S.D.; Stein B.S.; Mohagheghpour N.; Benike C.J.; Engleman E.G.; Evidence that T cell activation is required for HIV-1 entry in CD4+ lymphocytes. J Immunol 1989,142(3),773-780","journal-title":"J Immunol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0966-842X(96)81547-2","volume":"4","author":"Michie C.A.","year":"1996","unstructured":"Michie C.A.; Recent developments in theories of pathogenesis of AIDS. Trends Microbiol 1996,4(8),299","journal-title":"Trends Microbiol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/0966-842X(96)10044-5","volume":"4","author":"Antia R.","year":"1996","unstructured":"Antia R.; Halloran M.E.; Recent developments in theories of pathogenesis of AIDS. Trends Microbiol 1996,4(7),282-285","journal-title":"Trends Microbiol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.biochem.67.1.1","volume":"67","author":"Frankel A.D.","year":"1998","unstructured":"Frankel A.D.; Young J.A.; HIV-1: Fifteen proteins and an RNA. Annu Rev Biochem 1998,67,1-25","journal-title":"Annu Rev Biochem"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"991","DOI":"10.2174\/1568026043388529","volume":"4","author":"Rodr\u00edguez-Barrios F.","year":"2004","unstructured":"Rodr\u00edguez-Barrios F.; Gago F.; HIV protease inhibition: Limited recent progress and advances in understanding current pitfalls. Curr Top Med Chem 2004,4(9),991-1007","journal-title":"Curr Top Med Chem"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.4155\/fmc.13.89","volume":"5","author":"Huang L.","year":"2013","unstructured":"Huang L.; Chen C.; Understanding HIV-1 protease autoprocessing for novel therapeutic development. Future Med Chem 2013,5(11),1215-1229","journal-title":"Future Med Chem"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1021\/jm00112a001","volume":"34","author":"Huff J.R.","year":"1991","unstructured":"Huff J.R.; HIV protease: A novel chemotherapeutic target for AIDS. J Med Chem 1991,34(8),2305-2314","journal-title":"J Med Chem"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1146\/annurev.bi.62.070193.002551","volume":"62","author":"Wlodawer A.","year":"1993","unstructured":"Wlodawer A.; Erickson J.W.; Structure-based inhibitors of HIV-1 protease. Annu Rev Biochem 1993,62,543-585","journal-title":"Annu Rev Biochem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0167-4838(99)00273-3","volume":"1477","author":"Tomasselli A.G.","year":"2000","unstructured":"Tomasselli A.G.; Heinrikson R.L.; Targeting the HIV-protease in AIDS therapy: A current clinical perspective. Biochim Biophys Acta 2000,1477(1-2),189-214","journal-title":"Biochim Biophys Acta"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2174\/0929867003375146","volume":"7","author":"Lebon F.","year":"2000","unstructured":"Lebon F.; Ledecq M.; Approaches to the design of effective HIV-1 protease inhibitors. Curr Med Chem 2000,7(4),455-477","journal-title":"Curr Med Chem"},{"key":"ref=15","unstructured":"US FDA. Antiretroviral drugs used in the treatment of HIV infection (Accessed 2018).","journal-title":"Antiretroviral drugs used in the treatment of HIV infection"},{"key":"ref=16","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a007161","volume":"2","author":"Arts E.J.","year":"2012","unstructured":"Arts E.J.; Hazuda D.J.; HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2012,2(4)","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1126\/science.331.6019.848","volume":"331","author":"Konstantinov I.","year":"2011","unstructured":"Konstantinov I.; Stefanov Y.; Kovalevsky A.; Voronin Y.; Science 2011,331(6019),848-849","journal-title":"Science"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2174\/1871526517666170505122800","volume":"18","author":"Lu D.Y.","year":"2018","unstructured":"Lu D.Y.; Wu H.Y.; Yarla N.S.; Xu B.; Ding J.; Lu T.R.; HAART in HIV\/AIDS Treatments: Future trends. Infect Disord Drug Targets 2018,18(1),15-22","journal-title":"Infect Disord Drug Targets"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1159\/000445852","volume":"43","author":"Seitz R.","year":"2016","unstructured":"Seitz R.; Human immunodeficiency virus (HIV). Transfus Med Hemother 2016,43(3),203-222","journal-title":"Transfus Med Hemother"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/82_2015_437","volume":"389","author":"Goodsell D.S.","year":"2015","unstructured":"Goodsell D.S.; Illustrations of the HIV life cycle. Curr Top Microbiol Immunol 2015,389,243-252","journal-title":"Curr Top Microbiol Immunol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1742-4690-1-9","volume":"1","author":"Nisole S.","year":"2004","unstructured":"Nisole S.; Sa\u00efb A.; Early steps of retrovirus replicative cycle. Retrovirology 2004,1,9","journal-title":"Retrovirology"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/jbcpp-2014-0018","volume":"26","author":"Kurapati K.R.","year":"2015","unstructured":"Kurapati K.R.; Samikkannu T.; Atluri V.S.; Nair M.P.; Cell cycle checkpoints and pathogenesis of HIV-1 infection: A brief overview. J Basic Clin Physiol Pharmacol 2015,26(1),1-11","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"ref=23","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006866","volume":"2","author":"Wilen C.B.","year":"2012","unstructured":"Wilen C.B.; Tilton J.C.; Doms R.W.; HIV: Cell binding and entry. Cold Spring Harb Perspect Med 2012,2(8)","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3390\/v2051181","volume":"2","author":"Men\u00e9ndez-Arias L.","year":"2010","unstructured":"Men\u00e9ndez-Arias L.; Special issue: Retroviral enzymes. Viruses 2010,2(5),1181-1184","journal-title":"Viruses"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3390\/v2010111","volume":"2","author":"Desfarges S.","year":"2010","unstructured":"Desfarges S.; Ciuffi A.; Retroviral integration site selection. Viruses 2010,2(1),111-130","journal-title":"Viruses"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3390\/v2010213","volume":"2","author":"Isel C.","year":"2010","unstructured":"Isel C.; Ehresmann C.; Marquet R.; Initiation of HIV reverse transcription. Viruses 2010,2(1),213-243","journal-title":"Viruses"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"280","DOI":"10.18388\/pb.2016_27","volume":"62","author":"Skalka A.M.","year":"2016","unstructured":"Skalka A.M.; Andrake M.D.; Katz R.A.; Successes and challenges with retroviral enzymes. Postepy Biochem 2016,62(3),280-285","journal-title":"Postepy Biochem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1146\/annurev.bi.63.070194.001025","volume":"63","author":"Katz R.A.","year":"1994","unstructured":"Katz R.A.; Skalka A.M.; The retroviral enzymes. Annu Rev Biochem 1994,63,133-173","journal-title":"Annu Rev Biochem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/viro.1998.9398","volume":"251","author":"Freed E.O.","year":"1998","unstructured":"Freed E.O.; HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 1998,251(1),1-15","journal-title":"Virology"},{"key":"ref=30","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a007443","volume":"2","author":"Swanstrom R.","year":"2012","unstructured":"Swanstrom R.; Coffin J.; HIV-1 pathogenesis: The virus. Cold Spring Harb Perspect Med 2012,2(12)","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1074\/jbc.TM118.004156","volume":"294","author":"Bond J.S.","year":"2019","unstructured":"Bond J.S.; Proteases: History, discovery, and roles in health and disease. J Biol Chem 2019,294(5),1643-1651","journal-title":"J Biol Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1021\/cr040669e","volume":"105","author":"Tyndall J.D.A.","year":"2005","unstructured":"Tyndall J.D.A.; Nall T.; Fairlie D.P.; Proteases universally recognize beta strands in their active sites. Chem Rev 2005,105(3),973-999","journal-title":"Chem Rev"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/med.21475","volume":"38","author":"Agbowuro A.A.","year":"2018","unstructured":"Agbowuro A.A.; Huston W.M.; Gamble A.B.; Tyndall J.D.A.; Proteases and protease inhibitors in infectious diseases. Med Res Rev 2018,38(4),1295-1331","journal-title":"Med Res Rev"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.bbrc.2012.08.015","volume":"425","author":"Schechter I.","year":"2012","unstructured":"Schechter I.; Berger A.; On the size of the active site in proteases. I. Papain. 1967. Biochem Biophys Res Commun 2012,425(3),497-502","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0006-291X(67)80055-X","volume":"27","author":"Schechter I.","year":"1967","unstructured":"Schechter I.; Berger A.; On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967,27(2),157-162","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=36","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006924","volume":"2","author":"Sundquist W.I.","year":"2012","unstructured":"Sundquist W.I.; Kr\u00e4usslich H.G.; HIV-1 assembly, budding, and maturation. Cold Spring Harb Perspect Med 2012,2(7)","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"4686","DOI":"10.1073\/pnas.85.13.4686","volume":"85","author":"Kohl N.E.","year":"1988","unstructured":"Kohl N.E.; Emini E.A.; Schleif W.A.; Davis L.J.; Heimbach J.C.; Dixon R.A.; Scolnick E.M.; Sigal I.S.; Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988,85(13),4686-4690","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1126\/science.2420008","volume":"231","author":"Kramer R.A.","year":"1986","unstructured":"Kramer R.A.; Schaber M.D.; Skalka A.M.; Ganguly K.; Wong-Staal F.; Reddy E.P.; HTLV-III gag protein is processed in yeast cells by the virus pol-protease. Science 1986,231(4745),1580-1584","journal-title":"Science"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1089\/aid.1992.8.153","volume":"8","author":"Debouck C.","year":"1992","unstructured":"Debouck C.; The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum Retroviruses 1992,8(2),153-164","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref=40","author":"Nelson D.L.","year":"2012","unstructured":"Nelson D.L.; Cox M.M.; Lehninger principles of biochemistry. Macmillan Learning 2012","journal-title":"Macmillan Learning"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1126\/science.2183354","volume":"248","author":"Roberts N.A.","year":"1990","unstructured":"Roberts N.A.; Martin J.A.; Kinchington D.; Broadhurst A.V.; Craig J.C.; Duncan I.B.; Galpin S.A.; Handa B.K.; Kay J.; Kr\u00f6hn A.; Rational design of peptide-based HIV proteinase inhibitors. Science 1990,248(4953),358-361","journal-title":"Science"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1021\/jm00115a028","volume":"34","author":"Krohn A.","year":"1991","unstructured":"Krohn A.; Redshaw S.; Ritchie J.C.; Graves B.J.; Hatada M.H.; Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. J Med Chem 1991,34(11),3340-3342","journal-title":"J Med Chem"},{"key":"ref=43","first-page":"1","volume":"Vol. 7","author":"Ghosh A.","year":"2010","unstructured":"Ghosh A.; Anderson D.D.; Mitsuya H.; The FDA approved HIV-1 protease inhibitors for treatment of HIV\/AIDS. Burger\u2019s Medicinal Chemistry and Drug Discovery 2010,Vol. 7,1-74","journal-title":"Burger\u2019s Medicinal Chemistry and Drug Discovery"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0969-2126(02)00720-7","volume":"10","author":"Prabu-Jeyabalan M.","year":"2002","unstructured":"Prabu-Jeyabalan M.; Nalivaika E.; Schiffer C.A.; Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 2002,10(3),369-381","journal-title":"Structure"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"6099","DOI":"10.1021\/ja076558p","volume":"130","author":"Altman M.D.","year":"2008","unstructured":"Altman M.D.; Ali A.; Reddy G.S.; Nalam M.N.; Anjum S.G.; Cao H.; Chellappan S.; Kairys V.; Fernandes M.X.; Gilson M.K.; Schiffer C.A.; Rana T.M.; Tidor B.; HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants. J Am Chem Soc 2008,130(19),6099-6113","journal-title":"J Am Chem Soc"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1128\/AAC.50.4.1518-1521.2006","volume":"50","author":"Prabu-Jeyabalan M.","year":"2006","unstructured":"Prabu-Jeyabalan M.; King N.M.; Nalivaika E.A.; Heilek-Snyder G.; Cammack N.; Schiffer C.A.; Substrate envelope and drug resistance: Crystal structure of RO1 in complex with wild-type human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 2006,50(4),1518-1521","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1128\/JVI.78.6.3123-3132.2004","volume":"78","author":"Logsdon B.C.","year":"2004","unstructured":"Logsdon B.C.; Vickrey J.F.; Martin P.; Proteasa G.; Koepke J.I.; Terlecky S.R.; Wawrzak Z.; Winters M.A.; Merigan T.C.; Kovari L.C.; Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity. J Virol 2004,78(6),3123-3132","journal-title":"J Virol"},{"key":"ref=48","first-page":"131","volume":"10","author":"Lefebvre E.","year":"2008","unstructured":"Lefebvre E.; Schiffer C.A.; Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev 2008,10(3),131-142","journal-title":"AIDS Rev"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1021\/cb400468c","volume":"8","author":"Shen Y.","year":"2013","unstructured":"Shen Y.; Altman M.D.; Ali A.; Nalam M.N.; Cao H.; Rana T.M.; Schiffer C.A.; Tidor B.; Testing the substrate-envelope hypothesis with designed pairs of compounds. ACS Chem Biol 2013,8(11),2433-2441","journal-title":"ACS Chem Biol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.chembiol.2013.07.014","volume":"20","author":"Nalam M.N.","year":"2013","unstructured":"Nalam M.N.; Ali A.; Reddy G.S.; Cao H.; Anjum S.G.; Altman M.D.; Yilmaz N.K.; Tidor B.; Rana T.M.; Schiffer C.A.; Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance. Chem Biol 2013,20(9),1116-1124","journal-title":"Chem Biol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1248\/cpb.39.2465","volume":"39","author":"Mimoto T.","year":"1991","unstructured":"Mimoto T.; Imai J.; Tanaka S.; Hattori N.; Takahashi O.; Kisanuki S.; Nagano Y.; Shintani M.; Hayashi H.; Sakikawa H.; Rational design and synthesis of a novel class of active site-targeted HIV protease inhibitors containing a hydroxymethylcarbonyl isostere. Use of phenylnorstatine or allophenylnorstatine as a transition-state mimic. Chem Pharm Bull (Tokyo) 1991,39(9),2465-2467","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0006-291X(05)81274-4","volume":"180","author":"Raju B.","year":"1991","unstructured":"Raju B.; Deshpande M.S.; Investigating the stereochemistry of binding to HIV-1 protease with inhibitors containing isomers of 4-amino-3-hydroxy-5-phenylpentanoic acid. Biochem Biophys Res Commun 1991,180(1),187-190","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/0006-291X(92)91137-F","volume":"188","author":"Fehrentz J.A.","year":"1992","unstructured":"Fehrentz J.A.; Chomier B.; Bignon E.; Venaud S.; Chermann J.C.; Nisato D.; Statine based tripeptides as potent inhibitors of HIV-1 replication. Biochem Biophys Res Commun 1992,188(2),873-878","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1248\/cpb.41.1369","volume":"41","author":"Sakurai M.","year":"1993","unstructured":"Sakurai M.; Sugano M.; Handa H.; Komai T.; Yagi R.; Nishigaki T.; Yabe Y.; Studies of HIV-1 protease inhibitors. I. Incorporation of a reduced peptide, simple aminoalcohol, and statine analog at the scissile site of substrate sequences. Chem Pharm Bull (Tokyo) 1993,41(8),1369-1377","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1021\/jm00085a020","volume":"35","author":"Tam T.F.","year":"1992","unstructured":"Tam T.F.; Carri\u00e8re J.; MacDonald D.; Castelhano A.L.; Pliura D.H.; Dewdney N.J.; Thomas E.M.; Bach C.; Barnett J.; Chan H.; Intriguing structure-activity relations underlie the potent inhibition of HIV protease by norstatine-based peptides. J Med Chem 1992,35(7),1318-1320","journal-title":"J Med Chem"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"11867","DOI":"10.1021\/ja00153a008","volume":"117","author":"H. Slee","year":"1995","unstructured":"H. Slee; D.; L.Laslo, K.; H. Elder, J.; R.Ollmann, I.; Gustchina, A.; Kervinen, J.; Zdanov, A.; Wlodawer, A.; Wong, C.-H. Selectivity in the inhibition of HIV and FIV protease: Inhibitory and mechanistic studies of pyrrolidine-containing. alpha.-keto amide and hydroxyethylamine core structures. J Am Chem Soc 1995,117(48),11867-11878","journal-title":"J Am Chem Soc"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jmb.2004.02.052","volume":"338","author":"Tie Y.","year":"2004","unstructured":"Tie Y.; Boross P.I.; Wang Y.F.; Gaddis L.; Hussain A.K.; Leshchenko S.; Ghosh A.K.; Louis J.M.; Harrison R.W.; Weber I.T.; High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J Mol Biol 2004,338(2),341-352","journal-title":"J Mol Biol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1021\/ml100289m","volume":"2","author":"Ghosh A.K.","year":"2011","unstructured":"Ghosh A.K.; Martyr C.D.; Steffey M.; Wang Y.F.; Agniswamy J.; Amano M.; Weber I.T.; Mitsuya H.; Design of substituted bis-Tetrahydrofuran (bis-THF)-derived potent HIV-1 protease inhibitors, protein-ligand X-ray structure, and convenient syntheses of bis-THF and substituted bis-THF ligands. ACS Med Chem Lett 2011,2(4),298-302","journal-title":"ACS Med Chem Lett"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1021\/jm1012787","volume":"54","author":"Ghosh A.K.","year":"2011","unstructured":"Ghosh A.K.; Chapsal B.D.; Baldridge A.; Steffey M.P.; Walters D.E.; Koh Y.; Amano M.; Mitsuya H.; Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation. J Med Chem 2011,54(2),622-634","journal-title":"J Med Chem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"5890","DOI":"10.1021\/jm200649p","volume":"54","author":"Ghosh A.K.","year":"2011","unstructured":"Ghosh A.K.; Chapsal B.D.; Parham G.L.; Steffey M.; Agniswamy J.; Wang Y.F.; Amano M.; Weber I.T.; Mitsuya H.; Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure. J Med Chem 2011,54(16),5890-5901","journal-title":"J Med Chem"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1016\/j.bmcl.2012.01.061","volume":"22","author":"Ghosh A.K.","year":"2012","unstructured":"Ghosh A.K.; Chapsal B.D.; Steffey M.; Agniswamy J.; Wang Y.F.; Amano M.; Weber I.T.; Mitsuya H.; Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors. Bioorg Med Chem Lett 2012,22(6),2308-2311","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.1021\/jm900303m","volume":"52","author":"Ghosh A.K.","year":"2009","unstructured":"Ghosh A.K.; Leshchenko-Yashchuk S.; Anderson D.D.; Baldridge A.; Noetzel M.; Miller H.B.; Tie Y.; Wang Y.F.; Koh Y.; Weber I.T.; Mitsuya H.; Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1\u2032-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies. J Med Chem 2009,52(13),3902-3914","journal-title":"J Med Chem"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1021\/ja058211x","volume":"128","author":"Hornak V.","year":"2006","unstructured":"Hornak V.; Okur A.; Rizzo R.C.; Simmerling C.; HIV-1 protease flaps spontaneously close to the correct structure in simulations following manual placement of an inhibitor into the open state. J Am Chem Soc 2006,128(9),2812-2813","journal-title":"J Am Chem Soc"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"13360","DOI":"10.1021\/ja065133k","volume":"128","author":"Layten M.","year":"2006","unstructured":"Layten M.; Hornak V.; Simmerling C.; The open structure of a multi-drug-resistant HIV-1 protease is stabilized by crystal packing contacts. J Am Chem Soc 2006,128(41),13360-13361","journal-title":"J Am Chem Soc"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.drudis.2006.12.011","volume":"12","author":"Hornak V.","year":"2007","unstructured":"Hornak V.; Simmerling C.; Targeting structural flexibility in HIV-1 protease inhibitor binding. Drug Discov Today 2007,12(3-4),132-138","journal-title":"Drug Discov Today"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S0969-2126(99)80172-5","volume":"7","author":"Ishima R.","year":"1999","unstructured":"Ishima R.; Freedberg D.I.; Wang Y-X.; Louis J.M.; Torchia D.A.; Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function. Structure 1999,7(9),1047-1055","journal-title":"Structure"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1073\/pnas.0508452103","volume":"103","author":"Hornak V.","year":"2006","unstructured":"Hornak V.; Okur A.; Rizzo R.C.; Simmerling C.; HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations. Proc Natl Acad Sci USA 2006,103(4),915-920","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/cmdc.200500008","volume":"1","author":"Specker E.","year":"2006","unstructured":"Specker E.; B\u00f6ttcher J.; Brass S.; Heine A.; Lilie H.; Schoop A.; M\u00fcller G.; Griebenow N.; Klebe G.; Unexpected novel binding mode of pyrrolidine-based aspartyl protease inhibitors: design, synthesis and crystal structure in complex with HIV protease. ChemMedChem 2006,1(1),106-117","journal-title":"ChemMedChem"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1002\/cmdc.200800113","volume":"3","author":"B\u00f6ttcher J.","year":"2008","unstructured":"B\u00f6ttcher J.; Blum A.; D\u00f6rr S.; Heine A.; Diederich W.E.; Klebe G.; Targeting the open-flap conformation of HIV-1 protease with pyrrolidine-based inhibitors. ChemMedChem 2008,3(9),1337-1344","journal-title":"ChemMedChem"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"15394","DOI":"10.1073\/pnas.0507577102","volume":"102","author":"C\u00edgler P.","year":"2005","unstructured":"C\u00edgler P.; Koz\u00edsek M.; Rez\u00e1cov\u00e1 P.; Brynda J.; Otwinowski Z.; Pokorn\u00e1 J.; Plesek J.; Gr\u00fcner B.; Doleckov\u00e1-Maresov\u00e1 L.; M\u00e1sa M.; Sedl\u00e1cek J.; Bodem J.; Kr\u00e4usslich H.G.; Kr\u00e1l V.; Konvalinka J.; From nonpeptide toward noncarbon protease inhibitors: metallacarboranes as specific and potent inhibitors of HIV protease. Proc Natl Acad Sci USA 2005,102(43),15394-15399","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1126\/science.8278812","volume":"263","author":"Lam P.Y.","year":"1994","unstructured":"Lam P.Y.; Jadhav P.K.; Eyermann C.J.; Hodge C.N.; Ru Y.; Bacheler L.T.; Meek J.L.; Otto M.J.; Rayner M.M.; Wong Y.N.; Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 1994,263(5145),380-384","journal-title":"Science"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"12325","DOI":"10.1074\/jbc.273.20.12325","volume":"273","author":"Ala P.J.","year":"1998","unstructured":"Ala P.J.; DeLoskey R.J.; Huston E.E.; Jadhav P.K.; Lam P.Y.; Eyermann C.J.; Hodge C.N.; Schadt M.C.; Lewandowski F.A.; Weber P.C.; McCabe D.D.; Duke J.L.; Chang C.H.; Molecular recognition of cyclic urea HIV-1 protease inhibitors. J Biol Chem 1998,273(20),12325-12331","journal-title":"J Biol Chem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1021\/jo951847u","volume":"61","author":"Pierce M.E.","year":"1996","unstructured":"Pierce M.E.; Harris G.D.; Islam Q.; Radesca L.A.; Storace L.; Waltermire R.E.; Wat E.; Jadhav P.K.; Emmett G.C.; Stereoselective synthesis of HIV-1 protease inhibitor, DMP 323. J Org Chem 1996,61(2),444-450","journal-title":"J Org Chem"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3390\/v1031209","volume":"1","author":"Pokorn\u00e1 J.","year":"2009","unstructured":"Pokorn\u00e1 J.; Machala L.; Rez\u00e1\u010dov\u00e1 P.; Konvalinka J.; Current and novel inhibitors of HIV protease. Viruses 2009,1(3),1209-1239","journal-title":"Viruses"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1021\/acs.jmedchem.5b01697","volume":"59","author":"Ghosh A.K.","year":"2016","unstructured":"Ghosh A.K.; Osswald H.L.; Prato G.; Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV\/AIDS. J Med Chem 2016,59(11),5172-5208","journal-title":"J Med Chem"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1021\/jm9602571","volume":"39","author":"Lam P.Y.","year":"1996","unstructured":"Lam P.Y.; Ru Y.; Jadhav P.K.; Aldrich P.E.; DeLucca G.V.; Eyermann C.J.; Chang C.H.; Emmett G.; Holler E.R.; Daneker W.F.; Li L.; Confalone P.N.; McHugh R.J.; Han Q.; Li R.; Markwalder J.A.; Seitz S.P.; Sharpe T.R.; Bacheler L.T.; Rayner M.M.; Klabe R.M.; Shum L.; Winslow D.L.; Kornhauser D.M.; Hodge C.N.; Cyclic HIV protease inhibitors: Synthesis, conformational analysis, P2\/P2\u2032 structure-activity relationship, and molecular recognition of cyclic ureas. J Med Chem 1996,39(18),3514-3525","journal-title":"J Med Chem"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S0960-894X(98)00119-X","volume":"8","author":"Patel M.","year":"1998","unstructured":"Patel M.; Bacheler L.T.; Rayner M.M.; Cordova B.C.; Klabe R.M.; Erickson-Viitanen S.; Seitz S.P.; The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1\/P1\u2032 residues. Bioorg Med Chem Lett 1998,8(7),823-828","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1248\/cpb.48.1310","volume":"48","author":"Mimoto T.","year":"2000","unstructured":"Mimoto T.; Hattori N.; Takaku H.; Kisanuki S.; Fukazawa T.; Terashima K.; Kato R.; Nojima S.; Misawa S.; Ueno T.; Imai J.; Enomoto H.; Tanaka S.; Sakikawa H.; Shintani M.; Hayashi H.; Kiso Y.; Structure-activity relationship of orally potent tripeptide-based HIV protease inhibitors containing hydroxymethylcarbonyl isostere. Chem Pharm Bull (Tokyo) 2000,48(9),1310-1326","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1089\/aid.1994.10.735","volume":"10","author":"Kageyama S.","year":"1994","unstructured":"Kageyama S.; Hoekzema D.T.; Murakawa Y.; Kojima E.; Shirasaka T.; Kempf D.J.; Norbeck D.W.; Erickson J.; Mitsuya H.A.; C2 symmetry-based HIV protease inhibitor, A77003, irreversibly inhibits infectivity of HIV-1 in vitro. AIDS Res Hum Retroviruses 1994,10(6),735-743","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/BF02171654","volume":"1","author":"Appelt K.","year":"1993","unstructured":"Appelt K.; Crystal structures of HIV-1 protease-inhibitor complexes. Perspect Drug Discov Des 1993,1(1),23-48","journal-title":"Perspect Drug Discov Des"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1021\/cr960370z","volume":"97","author":"Babine R.E.","year":"1997","unstructured":"Babine R.E.; Bender S.L.; Molecular recognition of proteinminus signligand complexes: Applications to drug design. Chem Rev 1997,97(5),1359-1472","journal-title":"Chem Rev"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"9752","DOI":"10.1073\/pnas.86.24.9752","volume":"86","author":"Dreyer G.B.","year":"1989","unstructured":"Dreyer G.B.; Metcalf B.W.; Tomaszek T.A.; Carr T.J.; Chandler A.C.; Hyland L.; Fakhoury S.A.; Magaard V.W.; Moore M.L.; Strickler J.E.; Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors. Proc Natl Acad Sci USA 1989,86(24),9752-9756","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/343090a0","volume":"343","author":"Meek T.D.","year":"1990","unstructured":"Meek T.D.; Lambert D.M.; Dreyer G.B.; Carr T.J.; Tomaszek T.A.; Moore M.L.; Strickler J.E.; Debouck C.; Hyland L.J.; Matthews T.J.; Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature 1990,343(6253),90-92","journal-title":"Nature"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"6646","DOI":"10.1021\/bi00144a004","volume":"31","author":"Dreyer G.B.","year":"1992","unstructured":"Dreyer G.B.; Lambert D.M.; Meek T.D.; Carr T.J.; Tomaszek T.A.; Fernandez A.V.; Bartus H.; Cacciavillani E.; Hassell A.M.; Minnich M.; Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays. Biochemistry 1992,31(29),6646-6659","journal-title":"Biochemistry"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1021\/ja00108a056","volume":"117","author":"Kim E.E.","year":"1995","unstructured":"Kim E.E.; Baker C.T.; Dwyer M.D.; Murcko M.A.; Rao B.G.; Tung R.D.; Navia M.A.; Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J Am Chem Soc 1995,117(3),1181-1182","journal-title":"J Am Chem Soc"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S0960-894X(01)80367-X","volume":"4","author":"Kaldor S.W.","year":"1994","unstructured":"Kaldor S.W.; Hammond M.; Dressman B.A.; Fritz J.E.; Crowell T.A.; Hermann R.A.; New dipeptide isosteres useful for the inhibition of HIV-1 protease. Bioorg Med Chem Lett 1994,4(11),1385-1390","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1021\/op990202j","volume":"4","author":"Stoner E.J.","year":"2000","unstructured":"Stoner E.J.; Cooper A.J.; Dickman D.A.; Kolaczkowski L.; Lallaman J.E.; Liu J-H.; Oliver-Shaffer P.A.; Patel K.M.; Paterson J.B.; Plata D.J.; Riley D.A.; Sham H.L.; Stengel P.J.; Tien J-H.J.; Synthesis of HIV protease inhibitor ABT-378 (lopinavir). Org Process Res Dev 2000,4(4),264-269","journal-title":"Org Process Res Dev"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1021\/jm970636+","volume":"41","author":"Kempf D.J.","year":"1998","unstructured":"Kempf D.J.; Sham H.L.; Marsh K.C.; Flentge C.A.; Betebenner D.; Green B.E.; McDonald E.; Vasavanonda S.; Saldivar A.; Wideburg N.E.; Kati W.M.; Ruiz L.; Zhao C.; Fino L.; Patterson J.; Molla A.; Plattner J.J.; Norbeck D.W.; Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. J Med Chem 1998,41(4),602-617","journal-title":"J Med Chem"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0968-0896(00)82058-1","volume":"2","author":"Munoz B.","year":"1994","unstructured":"Munoz B.; Giam C.Z.; Wong C.H.; Alpha-ketoamide Phe-Pro isostere as a new core structure for the inhibition of HIV protease. Bioorg Med Chem 1994,2(10),1085-1090","journal-title":"Bioorg Med Chem"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/S0968-0896(98)00247-8","volume":"7","author":"Wolfenden R.","year":"1999","unstructured":"Wolfenden R.; Conformational aspects of inhibitor design: Enzyme-substrate interactions in the transition state. Bioorg Med Chem 1999,7(5),647-652","journal-title":"Bioorg Med Chem"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1248\/cpb.41.1369","volume":"41","author":"Sakurai M.","year":"1993","unstructured":"Sakurai M.; Sugano M.; Handa H.; Komai T.; Yagi R.; Nishigaki T.; Yabe Y.; Studies of HIV-1 protease inhibitors. I. Incorporation of a reduced peptide, simple aminoalcohol, and statine analog at the scissile site of substrate sequences. Chem Pharm Bull (Tokyo) 1993,41(8),1369-1377","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"11867","DOI":"10.1021\/ja00153a008","volume":"117","author":"Slee D.H.","year":"1995","unstructured":"Slee D.H.; Laslo K.L.; Elder J.H.; Ollmann I.R.; Gustchina A.; Kervinen J.; Zdanov A.; Wlodawer A.; Wong C-H.; Selectivity in the inhibition of HIV and FIV protease: Inhibitory and mechanistic studies of pyrrolidine-containing. alpha.-keto amide and hydroxyethylamine Core Structures. J Am Chem Soc 1995,117(48),11867-11878","journal-title":"J Am Chem Soc"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1517\/13543784.11.9.1295","volume":"11","author":"Piliero P.J.","year":"2002","unstructured":"Piliero P.J.; Atazanavir: A novel HIV-1 protease inhibitor. Expert Opin Investig Drugs 2002,11(9),1295-1301","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.2165\/00003495-200363160-00003","volume":"63","author":"Goldsmith D.R.","year":"2003","unstructured":"Goldsmith D.R.; Perry C.M.; Atazanavir. Drugs 2003,63(16),1679-1693","journal-title":"Drugs"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1021\/jm960441m","volume":"40","author":"Skulnick H.I.","year":"1997","unstructured":"Skulnick H.I.; Johnson P.D.; Aristoff P.A.; Morris J.K.; Lovasz K.D.; Howe W.J.; Watenpaugh K.D.; Janakiraman M.N.; Anderson D.J.; Reischer R.J.; Schwartz T.M.; Banitt L.S.; Tomich P.K.; Lynn J.C.; Horng M-M.; Chong K-T.; Hinshaw R.R.; Dolak L.A.; Seest E.P.; Schwende F.J.; Rush B.D.; Howard G.M.; Toth L.N.; Wilkinson K.R.; Romines K.R.; Johnson C.W.; Cole S.L.; Zaya R.M.; Zipp G.L.; Possert P.L.; Dalga R.J.; Zhong W-Z.; Williams M.G.; Romines K.R.; Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones. J Med Chem 1997,40(7),1149-1164","journal-title":"J Med Chem"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"12234","DOI":"10.1073\/pnas.1400027111","volume":"111","author":"Hayashi H.","year":"2014","unstructured":"Hayashi H.; Takamune N.; Nirasawa T.; Aoki M.; Morishita Y.; Das D.; Koh Y.; Ghosh A.K.; Misumi S.; Mitsuya H.; Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir. Proc Natl Acad Sci USA 2014,111(33),12234-12239","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1006\/jmbi.1998.2090","volume":"283","author":"Todd M.J.","year":"1998","unstructured":"Todd M.J.; Semo N.; Freire E.; The structural stability of the HIV-1 protease. J Mol Biol 1998,283(2),475-488","journal-title":"J Mol Biol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.antiviral.2006.03.015","volume":"72","author":"Davis D.A.","year":"2006","unstructured":"Davis D.A.; Brown C.A.; Singer K.E.; Wang V.; Kaufman J.; Stahl S.J.; Wingfield P.; Maeda K.; Harada S.; Yoshimura K.; Kosalaraksa P.; Mitsuya H.; Yarchoan R.; Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease. Antiviral Res 2006,72(2),89-99","journal-title":"Antiviral Res"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"28709","DOI":"10.1074\/jbc.M703938200","volume":"282","author":"Koh Y.","year":"2007","unstructured":"Koh Y.; Matsumi S.; Das D.; Amano M.; Davis D.A.; Li J.; Leschenko S.; Baldridge A.; Shioda T.; Yarchoan R.; Ghosh A.K.; Mitsuya H.; Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J Biol Chem 2007,282(39),28709-28720","journal-title":"J Biol Chem"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"10079","DOI":"10.1128\/JVI.05121-11","volume":"85","author":"Koh Y.","year":"2011","unstructured":"Koh Y.; Aoki M.; Danish M.L.; Aoki-Ogata H.; Amano M.; Das D.; Shafer R.W.; Ghosh A.K.; Mitsuya H.; Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1. J Virol 2011,85(19),10079-10089","journal-title":"J Virol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1021\/jm060576k","volume":"49","author":"Bannwarth L.","year":"2006","unstructured":"Bannwarth L.; Kessler A.; P\u00e8the S.; Collinet B.; Merabet N.; Boggetto N.; Sicsic S.; Reboud-Ravaux M.; Ongeri S.; Molecular tongs containing amino acid mimetic fragments: new inhibitors of wild-type and mutated HIV-1 protease dimerization. J Med Chem 2006,49(15),4657-4664","journal-title":"J Med Chem"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1002\/cmdc.201000308","volume":"5","author":"Vidu A.","year":"2010","unstructured":"Vidu A.; Dufau L.; Bannwarth L.; Soulier J.L.; Sicsic S.; Piarulli U.; Reboud-Ravaux M.; Ongeri S.; Toward the first nonpeptidic molecular tong inhibitor of wild-type and mutated HIV-1 protease dimerization. ChemMedChem 2010,5(11),1899-1906","journal-title":"ChemMedChem"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"6762","DOI":"10.1021\/jm300181j","volume":"55","author":"Dufau L.","year":"2012","unstructured":"Dufau L.; Marques Ressurrei\u00e7\u00e3o A.S.; Fanelli R.; Kihal N.; Vidu A.; Milcent T.; Soulier J.L.; Rodrigo J.; Desvergne A.; Leblanc K.; Bernadat G.; Crousse B.; Reboud-Ravaux M.; Ongeri S.; Carbonylhydrazide-based molecular tongs inhibit wild-type and mutated HIV-1 protease dimerization. J Med Chem 2012,55(15),6762-6775","journal-title":"J Med Chem"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1002\/cbic.201000248","volume":"11","author":"Lee S.G.","year":"2010","unstructured":"Lee S.G.; Chmielewski J.; Cross-linked peptoid-based dimerization inhibitors of HIV-1 protease. ChemBioChem 2010,11(11),1513-1516","journal-title":"ChemBioChem"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.chembiol.2005.02.004","volume":"12","author":"Bowman M.J.","year":"2005","unstructured":"Bowman M.J.; Byrne S.; Chmielewski J.; Switching between allosteric and dimerization inhibition of HIV-1 protease. Chem Biol 2005,12(4),439-444","journal-title":"Chem Biol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1021\/jm00172a002","volume":"33","author":"Kempf D.J.","year":"1990","unstructured":"Kempf D.J.; Norbeck D.W.; Codacovi L.; Wang X.C.; Kohlbrenner W.E.; Wideburg N.E.; Paul D.A.; Knigge M.F.; Vasavanonda S.; Craig-Kennard A.; Structure-based, C2 symmetric inhibitors of HIV protease. J Med Chem 1990,33(10),2687-2689","journal-title":"J Med Chem"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1021\/jm00055a003","volume":"36","author":"Kempf D.J.","year":"1993","unstructured":"Kempf D.J.; Codacovi L.; Wang X.C.; Kohlbrenner W.E.; Wideburg N.E.; Saldivar A.; Vasavanonda S.; Marsh K.C.; Bryant P.; Sham H.L.; Symmetry-based inhibitors of HIV protease. Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl-3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol. J Med Chem 1993,36(3),320-330","journal-title":"J Med Chem"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1126\/science.2200122","volume":"249","author":"Erickson J.","year":"1990","unstructured":"Erickson J.; Neidhart D.J.; VanDrie J.; Kempf D.J.; Wang X.C.; Norbeck D.W.; Plattner J.J.; Rittenhouse J.W.; Turon M.; Wideburg N.; Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science 1990,249(4968),527-533","journal-title":"Science"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1128\/AAC.39.7.1559","volume":"39","author":"Reedijk M.","year":"1995","unstructured":"Reedijk M.; Boucher C.A.; van Bommel T.; Ho D.D.; Tzeng T.B.; Sereni D.; Veyssier P.; Jurriaans S.; Granneman R.; Hsu A.; Safety, pharmacokinetics, and antiviral activity of A77003, a C2 symmetry-based human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 1995,39(7),1559-1564","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1073\/pnas.92.7.2484","volume":"92","author":"Kempf D.J.","year":"1995","unstructured":"Kempf D.J.; Marsh K.C.; Denissen J.F.; McDonald E.; Vasavanonda S.; Flentge C.A.; Green B.E.; Fino L.; Park C.H.; Kong X.P.; ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995,92(7),2484-2488","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/0968-0896(95)00069-S","volume":"3","author":"Budt K.H.","year":"1995","unstructured":"Budt K.H.; Peyman A.; Hansen J.; Knolle J.; Meichsner C.; Paessens A.; Ruppert D.; Stowasser B.; HIV protease inhibitor HOE\/BAY 793, structure-activity relationships in a series of C2-symmetric diols. Bioorg Med Chem 1995,3(5),559-571","journal-title":"Bioorg Med Chem"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1016\/S0960-894X(01)80827-1","volume":"4","author":"Ettmayer P.","year":"1994","unstructured":"Ettmayer P.; H\u00fcbner M.; Andreas B.; Brigitte R.; Hubert G.; Novel, extended transition state mimic in HIV-1 protease inhibitors with peripheral C-2-symmetry. Bioorg Med Chem Lett 1994,4(24),2851-2856","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1089\/aid.1996.12.55","volume":"12","author":"Mo H.","year":"1996","unstructured":"Mo H.; Markowitz M.; Majer P.; Burt S.K.; Gulnik S.V.; Suvorov L.I.; Erickson J.W.; Ho D.D.; Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel inhibitors of HIV type 1 protease. AIDS Res Hum Retroviruses 1996,12(1),55-61","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/0076-6879(94)41072-0","volume":"241","author":"Kempf D.J.","year":"1994","unstructured":"Kempf D.J.; Design of symmetry-based, peptidomimetic inhibitors of human immunodeficiency virus protease. Methods Enzymol 1994,241,334-354","journal-title":"Methods Enzymol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"9382","DOI":"10.1021\/ja00024a061","volume":"113","author":"Bone R.","year":"1991","unstructured":"Bone R.; Vacca J.P.; Anderson P.S.; Holloway M.K.; X-ray crystal structure of the HIV protease complex with L-700,417, an inhibitor with pseudo C2 symmetry. J Am Chem Soc 1991,113(24),9382-9384","journal-title":"J Am Chem Soc"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/S0960-894X(00)80023-2","volume":"3","author":"Babine R.E.","year":"1993","unstructured":"Babine R.E.; Zhang N.; Schow S.R.; Jirousek M.R.; Johnson B.D.; Kerwar S.S.; Desai P.R.; Byrn R.A.; Hastings R.C.; Wick M.M.; Structure activity studies on pseudo-symmetrical HIV-1 protease inhibitors. Bioorg Med Chem Lett 1993,3(8),1589-1594","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=117","first-page":"889","volume":"47","author":"Marastoni M.","year":"1997","unstructured":"Marastoni M.; Bergonzoni M.; Bortolotti F.; Tomatis R.; Symmetry-based HIV protease inhibitors containing (S,S) or (R,R) tartaric acid core structure. Arzneimittelforschung 1997,47(7),889-892","journal-title":"Arzneimittelforschung"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0014-827X(02)00016-2","volume":"58","author":"Pe\u00e7anha E.P.","year":"2003","unstructured":"Pe\u00e7anha E.P.; Figueiredo L.J.; Brindeiro R.M.; Tanuri A.; Calazans A.R.; Antunes O.A.; Synthesis and anti-HIV activity of new C2 symmetric derivatives designed as HIV-1 protease inhibitors. Farmaco 2003,58(2),149-157","journal-title":"Farmaco"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1016\/j.ejmech.2009.05.016","volume":"44","author":"da Cunha E.F.","year":"2009","unstructured":"da Cunha E.F.; Sippl W.; de Castro Ramalho T.; Ceva Antunes O.A.; de Alencastro R.B.; Albuquerque M.G.; 3D-QSAR CoMFA\/CoMSIA models based on theoretical active conformers of HOE\/BAY-793 analogs derived from HIV-1 protease inhibitor complexes. Eur J Med Chem 2009,44(11),4344-4352","journal-title":"Eur J Med Chem"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1021\/jo0521504","volume":"71","author":"Arefalk A.","year":"2006","unstructured":"Arefalk A.; Wannberg J.; Larhed M.; Hallberg A.; Stereoselective synthesis of 3-aminoindan-1-ones and subsequent incorporation into HIV-1 protease inhibitors. J Org Chem 2006,71(3),1265-1268","journal-title":"J Org Chem"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejmech.2009.09.038","volume":"45","author":"Adrian Meredith J.","year":"2010","unstructured":"Adrian Meredith J.; Wallberg H.; Vrang L.; Oscarson S.; Parkes K.; Hallberg A.; Samuelsson B.; Design and synthesis of novel P2 substituents in diol-based HIV protease inhibitors. Eur J Med Chem 2010,45(1),160-170","journal-title":"Eur J Med Chem"},{"key":"ref=122","year":"2019","unstructured":"U.S. department of health and human services, National institutes of health, AIDS info Saquinavir. (Accessed on March 4, 2019 at2019"},{"key":"ref=123","first-page":"1","author":"James J.S.","year":"1995","unstructured":"James J.S.; Saquinavir (Invirase): First protease inhibitor approved--reimbursement, information hotline numbers. AIDS Treat News 1995(237),1-2","journal-title":"AIDS Treat News"},{"key":"ref=124","year":"2003","unstructured":"US Food and Drug Administration Roche, Fortovase\u00ae (saquinavir). (Accessed on March 4, 2019 at2003"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1136\/bmj.322.7299.1410","volume":"322","author":"Weller I.V.","year":"2001","unstructured":"Weller I.V.; Williams I.G.; ABC of AIDS. Antiretroviral drugs. BMJ 2001,322(7299),1410-1412","journal-title":"BMJ"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/00002030-199902040-00009","volume":"13","author":"Cameron D.W.","year":"1999","unstructured":"Cameron D.W.; Japour A.J.; Xu Y.; Hsu A.; Mellors J.; Farthing C.; Cohen C.; Poretz D.; Markowitz M.; Follansbee S.; Angel J.B.; McMahon D.; Ho D.; Devanarayan V.; Rode R.; Salgo M.; Kempf D.J.; Granneman R.; Leonard J.M.; Sun E.; Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 1999,13(2),213-224","journal-title":"AIDS"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1128\/AAC.44.10.2672-2678.2000","volume":"44","author":"Kilby J.M.","year":"2000","unstructured":"Kilby J.M.; Sfakianos G.; Gizzi N.; Siemon-Hryczyk P.; Ehrensing E.; Oo C.; Buss N.; Saag M.S.; Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob Agents Chemother 2000,44(10),2672-2678","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=128","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/135965350801300302","volume":"13","author":"Ananworanich J.","year":"2008","unstructured":"Ananworanich J.; Gayet-Ageron A.; Ruxrungtham K.; Chetchotisakd P.; Prasithsirikul W.; Kiertiburanakul S.; Munsakul W.; Raksakulkarn P.; Tansuphasawadikul S.; LeBraz M.; Jupimai T.; Ubolyam S.; Schutz M.; Hirschel B.; Long-term efficacy and safety of first-line therapy with once-daily saquinavir\/ritonavir. Antivir Ther (Lond) 2008,13(3),375-380","journal-title":"Antivir Ther (Lond)"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S0968-0896(00)82036-2","volume":"2","author":"Kempf D.J.","year":"1994","unstructured":"Kempf D.J.; Marsh K.C.; Fino L.C.; Bryant P.; Craig-Kennard A.; Sham H.L.; Zhao C.; Vasavanonda S.; Kohlbrenner W.E.; Wideburg N.E.; Design of orally bioavailable, symmetry-based inhibitors of HIV protease. Bioorg Med Chem 1994,2(9),847-858","journal-title":"Bioorg Med Chem"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1128\/AAC.41.3.654","volume":"41","author":"Kempf D.J.","year":"1997","unstructured":"Kempf D.J.; Marsh K.C.; Kumar G.; Rodrigues A.D.; Denissen J.F.; McDonald E.; Kukulka M.J.; Hsu A.; Granneman G.R.; Baroldi P.A.; Sun E.; Pizzuti D.; Plattner J.J.; Norbeck D.W.; Leonard J.M.; Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997,41(3),654-660","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1046\/j.1468-1293.2001.00063.x","volume":"2","author":"Moyle G.J.","year":"2001","unstructured":"Moyle G.J.; Back D.; Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001,2(2),105-113","journal-title":"HIV Med"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/jac\/dkh029","volume":"53","author":"Zeldin R.K.","year":"2004","unstructured":"Zeldin R.K.; Petruschke R.A.; Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004,53(1),4-9","journal-title":"J Antimicrob Chemother"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"9072","DOI":"10.1073\/pnas.1102278108","volume":"108","author":"Louis J.M.","year":"2011","unstructured":"Louis J.M.; Aniana A.; Weber I.T.; Sayer J.M.; Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitors. Proc Natl Acad Sci USA 2011,108(22),9072-9077","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1021\/jm00047a001","volume":"37","author":"Dorsey B.D.","year":"1994","unstructured":"Dorsey B.D.; Levin R.B.; McDaniel S.L.; Vacca J.P.; Guare J.P.; Darke P.L.; Zugay J.A.; Emini E.A.; Schleif W.A.; Quintero J.C.; L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J Med Chem 1994,37(21),3443-3451","journal-title":"J Med Chem"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.1073\/pnas.91.9.4096","volume":"91","author":"Vacca J.P.","year":"1994","unstructured":"Vacca J.P.; Dorsey B.D.; Schleif W.A.; Levin R.B.; McDaniel S.L.; Darke P.L.; Zugay J.; Quintero J.C.; Blahy O.M.; Roth E.; L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci USA 1994,91(9),4096-4100","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1126\/science.272.5270.1882","volume":"272","author":"Cohen J.","year":"1996","unstructured":"Cohen J.; Protease inhibitors: a tale of two companies. Science 1996,272(5270),1882-1883","journal-title":"Science"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/0-306-47384-4_11","volume":"11","author":"Lin J.H.","year":"1998","unstructured":"Lin J.H.; Ostovic D.; Vacca J.P.; The integration of medicinal chemistry, drug metabolism, and pharmaceutical research and development in drug discovery and development. The story of Crixivan, an HIV protease inhibitor. Pharm Biotechnol 1998,11,233-255","journal-title":"Pharm Biotechnol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s13365-010-0013-2","volume":"17","author":"Letendre S.L.","year":"2011","unstructured":"Letendre S.L.; Zheng J.C.; Kaul M.; Yiannoutsos C.T.; Ellis R.J.; Taylor M.J.; Marquie-Beck J.; Navia B.; Consortium H.I.V.N.; Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals. J Neurovirol 2011,17(1),63-69","journal-title":"J Neurovirol"},{"key":"ref=139","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025237","volume":"6","author":"Hresko R.C.","year":"2011","unstructured":"Hresko R.C.; Hruz P.W.; HIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose binding site of GLUTs with differing affinities for GLUT1 and GLUT4. PLoS One 2011,6(9)","journal-title":"PLoS One"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1089\/apc.1999.13.11","volume":"13","author":"Ho T.T.","year":"1999","unstructured":"Ho T.T.; Chan K.C.; Wong K.H.; Lee S.S.; Indinavir-associated facial lipodystrophy in HIV-infected patients. AIDS Patient Care STDS 1999,13(1),11-16","journal-title":"AIDS Patient Care STDS"},{"key":"ref=141","first-page":"825","volume":"88","author":"Krautheim A.","year":"1999","unstructured":"Krautheim A.; Indinavir-associated lipodystrophy Praxis (Bern 1994), 1999,88(7),825-287","journal-title":"Praxis (Bern 1994),"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"F37","DOI":"10.1097\/00002030-199806000-00001","volume":"12","author":"Viraben R.","year":"1998","unstructured":"Viraben R.; Aquilina C.; Indinavir-associated lipodystrophy. AIDS 1998,12(6),F37-F39","journal-title":"AIDS"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0022-5347(05)63936-5","volume":"169","author":"Nadler R.B.","year":"2003","unstructured":"Nadler R.B.; Rubenstein J.N.; Eggener S.E.; Loor M.M.; Smith N.D.; The etiology of urolithiasis in HIV infected patients. J Urol 2003,169(2),475-477","journal-title":"J Urol"},{"key":"ref=144","first-page":"1","volume":"277","author":"Capaldini L.","year":"1997","unstructured":"Capaldini L.; Protease inhibitors\u2019 metabolic side effects: cholesterol, triglycerides, blood sugar, and \u201ccrix belly\u201d. Interview with Lisa Capaldini, M.D. Interview by John S. James AIDS Treat News 1997,277,1-4","journal-title":"James AIDS Treat News"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1089\/088922203766774496","volume":"19","author":"Gonz\u00e1lez de Requena D.","year":"2003","unstructured":"Gonz\u00e1lez de Requena D.; Gallego O.; de Mendoza C.; Corral A.; Jim\u00e9nez-N\u00e1cher I.; Soriano V.; Indinavir plasma concentrations and resistance mutations in patients experiencing early virological failure. AIDS Res Hum Retroviruses 2003,19(6),457-459","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1021\/jm9704098","volume":"40","author":"Kaldor S.W.","year":"1997","unstructured":"Kaldor S.W.; Kalish V.J.; Davies J.F.; Shetty B.V.; Fritz J.E.; Appelt K.; Burgess J.A.; Campanale K.M.; Chirgadze N.Y.; Clawson D.K.; Dressman B.A.; Hatch S.D.; Khalil D.A.; Kosa M.B.; Lubbehusen P.P.; Muesing M.A.; Patick A.K.; Reich S.H.; Su K.S.; Tatlock J.H.; Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem 1997,40(24),3979-3985","journal-title":"J Med Chem"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1128\/AAC.40.2.292","volume":"40","author":"Patick A.K.","year":"1996","unstructured":"Patick A.K.; Mo H.; Markowitz M.; Appelt K.; Wu B.; Musick L.; Kalish V.; Kaldor S.; Reich S.; Ho D.; Webber S.; Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother 1996,40(2),292-297","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2165\/00003495-200059030-00014","volume":"59","author":"Bardsley-Elliot A.","year":"2000","unstructured":"Bardsley-Elliot A.; Plosker G.L.; Nelfinavir: An update on its use in HIV infection. Drugs 2000,59(3),581-620","journal-title":"Drugs"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1086\/313859","volume":"30","author":"Max B.","year":"2000","unstructured":"Max B.; Sherer R.; Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis 2000,30(Suppl. 2),S96-S116","journal-title":"Clin Infect Dis"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1093\/infdis\/172.5.1238","volume":"172","author":"Livington D.J.","year":"1995","unstructured":"Livington D.J.; Pazhanisamy S.; Porter D.J.; Partaledis J.A.; Tung R.D.; Painter G.R.; Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J Infect Dis 1995,172(5),1238-1245","journal-title":"J Infect Dis"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0166-3542(95)00916-7","volume":"29","author":"St Clair M.H.","year":"1996","unstructured":"St Clair M.H.; Millard J.; Rooney J.; Tisdale M.; Parry N.; Sadler B.M.; Blum M.R.; Painter G.; In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral Res 1996,29(1),53-56","journal-title":"Antiviral Res"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/pro.2019","volume":"21","author":"Tie Y.","year":"2012","unstructured":"Tie Y.; Wang Y.F.; Boross P.I.; Chiu T.Y.; Ghosh A.K.; Tozser J.; Louis J.M.; Harrison R.W.; Weber I.T.; Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors. Protein Sci 2012,21(3),339-350","journal-title":"Protein Sci"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1086\/341489","volume":"35","author":"Dub\u00e9 M.P.","year":"2002","unstructured":"Dub\u00e9 M.P.; Qian D.; Edmondson-Melan\u00e7on H.; Sattler F.R.; Goodwin D.; Martinez C.; Williams V.; Johnson D.; Buchanan T.A.; Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis 2002,35(4),475-481","journal-title":"Clin Infect Dis"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1468-1293.2004.00177.x","volume":"5","author":"Floridia M.","year":"2004","unstructured":"Floridia M.; Bucciardini R.; Fragola V.; Galluzzo C.M.; Giannini G.; Pirillo M.F.; Amici R.; Andreotti M.; Ricciardulli D.; Tomino C.; Vella S.; Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells\/microL). HIV Med 2004,5(1),1-10","journal-title":"HIV Med"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.ejmech.2017.07.044","volume":"139","author":"Subbaiah M.A.M.","year":"2017","unstructured":"Subbaiah M.A.M.; Meanwell N.A.; Kadow J.F.; Design strategies in the prodrugs of HIV-1 protease inhibitors to improve the pharmaceutical properties. Eur J Med Chem 2017,139,865-883","journal-title":"Eur J Med Chem"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.2174\/1381612033454441","volume":"9","author":"Vierling P.","year":"2003","unstructured":"Vierling P.; Greiner J.; Prodrugs of HIV protease inhibitors. Curr Pharm Des 2003,9(22),1755-1770","journal-title":"Curr Pharm Des"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1586\/14787210.5.3.349","volume":"5","author":"Torres H.A.","year":"2007","unstructured":"Torres H.A.; Arduino R.C.; Fosamprenavir calcium plus ritonavir for HIV infection. Expert Rev Anti Infect Ther 2007,5(3),349-363","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.clinthera.2006.05.011","volume":"28","author":"Gathe J.C.","year":"2006","unstructured":"Gathe J.C.; Wood R.; Sanne I.; DeJesus E.; Sch\u00fcrmann D.; Gladysz A.; Garris C.; Givens N.; Elston R.; Yeo J.; Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir\/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study. Clin Ther 2006,28(5),745-754","journal-title":"Clin Ther"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/pds.3543","volume":"23","author":"Judd A.","year":"2014","unstructured":"Judd A.; Duong T.; Galli L.; Goetghebuer T.; Ene L.; Noguera Julian A.; Ramos Amador J.T.; Pimenta J.M.; Thorne C.; Giaquinto C.; European P.; Paediatric H.I.V.C.C.E.; Post-licensing safety of fosamprenavir in HIV-infected children in Europe. Pharmacoepidemiol Drug Saf 2014,23(3),321-325","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1128\/AAC.42.12.3218","volume":"42","author":"Sham H.L.","year":"1998","unstructured":"Sham H.L.; Kempf D.J.; Molla A.; Marsh K.C.; Kumar G.N.; Chen C.M.; Kati W.; Stewart K.; Lal R.; Hsu A.; Betebenner D.; Korneyeva M.; Vasavanonda S.; McDonald E.; Saldivar A.; Wideburg N.; Chen X.; Niu P.; Park C.; Jayanti V.; Grabowski B.; Granneman G.R.; Sun E.; Japour A.J.; Leonard J.M.; Plattner J.J.; Norbeck D.W.; ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998,42(12),3218-3224","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2165\/11204950-000000000-00000","volume":"70","author":"Croxtall J.D.","year":"2010","unstructured":"Croxtall J.D.; Perry C.M.; Lopinavir\/ritonavir: A review of its use in the management of HIV-1 infection. Drugs 2010,70(14),1885-1915","journal-title":"Drugs"},{"key":"ref=162","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2147\/TCRM.S3285","volume":"4","author":"Chandwani A.","year":"2008","unstructured":"Chandwani A.; Shuter J.; Lopinavir\/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag 2008,4(5),1023-1033","journal-title":"Ther Clin Risk Manag"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.2165\/00003495-200666090-00012","volume":"66","author":"Oldfield V.","year":"2006","unstructured":"Oldfield V.; Plosker G.L.; Lopinavir\/ritonavir: A review of its use in the management of HIV infection. Drugs 2006,66(9),1275-1299","journal-title":"Drugs"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2165\/00003495-200363080-00004","volume":"63","author":"Cvetkovic R.S.","year":"2003","unstructured":"Cvetkovic R.S.; Goa K.L.; Lopinavir\/ritonavir: A review of its use in the management of HIV infection. Drugs 2003,63(8),769-802","journal-title":"Drugs"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1097\/00002030-200411050-00005","volume":"18","author":"Noor M.A.","year":"2004","unstructured":"Noor M.A.; Parker R.A.; O\u2019Mara E.; Grasela D.M.; Currie A.; Hodder S.L.; Fiedorek F.T.; Haas D.W.; The effects of HIV protease inhibitors atazanavir and lopinavir\/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004,18(16),2137-2144","journal-title":"AIDS"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1177\/0956462414523403","volume":"25","author":"Cresswell F.V.","year":"2014","unstructured":"Cresswell F.V.; Tomlins J.; Churchill D.R.; Walker-Bone K.; Richardson D.; Achilles tendinopathy following Kaletra (lopinavir\/ritonavir) use. Int J STD AIDS 2014,25(11),833-835","journal-title":"Int J STD AIDS"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1097\/QAD.0b013e328010f212","volume":"20","author":"Manfredi R.","year":"2006","unstructured":"Manfredi R.; Sabbatani S.; Serious, multi-organ hypersensitivity to lopinavir alone, involving cutaneous-mucous rash, and myeloid, liver, and kidney function. AIDS 2006,20(18),2399-2400","journal-title":"AIDS"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1021\/jm970873c","volume":"41","author":"Bold G.","year":"1998","unstructured":"Bold G.; F\u00e4ssler A.; Capraro H.G.; Cozens R.; Klimkait T.; Lazdins J.; Mestan J.; Poncioni B.; R\u00f6sel J.; Stover D.; Tintelnot-Blomley M.; Acemoglu F.; Beck W.; Boss E.; Eschbach M.; H\u00fcrlimann T.; Masso E.; Roussel S.; Ucci-Stoll K.; Wyss D.; Lang M.; New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development. J Med Chem 1998,41(18),3387-3401","journal-title":"J Med Chem"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1586\/14787210.1.3.403","volume":"1","author":"Becker S.","year":"2003","unstructured":"Becker S.; Atazanavir: improving the HIV protease inhibitor class. Expert Rev Anti Infect Ther 2003,1(3),403-413","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1097\/00126334-200408150-00003","volume":"36","author":"Squires K.","year":"2004","unstructured":"Squires K.; Lazzarin A.; Gatell J.M.; Powderly W.G.; Pokrovskiy V.; Delfraissy J.F.; Jemsek J.; Rivero A.; Rozenbaum W.; Schrader S.; Sension M.; Vibhagool A.; Thiry A.; Giordano M.; Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004,36(5),1011-1019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1097\/00002030-200312050-00007","volume":"17","author":"Murphy R.L.","year":"2003","unstructured":"Murphy R.L.; Sanne I.; Cahn P.; Phanuphak P.; Percival L.; Kelleher T.; Giordano M.; Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003,17(18),2603-2614","journal-title":"AIDS"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/154510970400300304","volume":"3","author":"Cahn P.E.","year":"2004","unstructured":"Cahn P.E.; Gatell J.M.; Squires K.; Percival L.D.; Piliero P.J.; Sanne I.A.; Shelton S.; Lazzarin A.; Odeshoo L.; Kelleher T.D.; Thiry A.; Giordano M.D.; Schnittman S.M.; Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials. J Int Assoc Physicians AIDS Care (Chic) 2004,3(3),92-98","journal-title":"J Int Assoc Physicians AIDS Care (Chic)"},{"key":"ref=173","first-page":"14","volume":"146","year":"2004","unstructured":"Simplified HIV therapy. Atazanavir: the first protease inhibitor with once daily administration. MMW Fortschr Med 2004,146(Spec No 1),14-16","journal-title":"MMW Fortschr Med"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/ki.2011.124","volume":"80","author":"Dauchy F.A.","year":"2011","unstructured":"Dauchy F.A.; Lawson-Ayayi S.; de La Faille R.; Bonnet F.; Rigothier C.; Mehsen N.; Miremont-Salam\u00e9 G.; Cazanave C.; Greib C.; Dabis F.; Dupon M.; Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int 2011,80(3),302-309","journal-title":"Kidney Int"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3109\/00365548.2012.712213","volume":"45","author":"Calza L.","year":"2013","unstructured":"Calza L.; Trapani F.; Salvadori C.; Magistrelli E.; Manfredi R.; Colangeli V.; Di Bari M.A.; Borderi M.; Viale P.; Incidence of renal toxicity in HIV-infected, antiretroviral-na\u00efve patients starting tenofovir\/emtricitabine associated with efavirenz, atazanavir\/ritonavir, or lopinavir\/ritonavir. Scand J Infect Dis 2013,45(2),147-154","journal-title":"Scand J Infect Dis"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2165\/00003088-200544100-00003","volume":"44","author":"Le Tiec C.","year":"2005","unstructured":"Le Tiec C.; Barrail A.; Goujard C.; Taburet A.M.; Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet 2005,44(10),1035-1050","journal-title":"Clin Pharmacokinet"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1128\/AAC.41.5.1058","volume":"41","author":"Poppe S.M.","year":"1997","unstructured":"Poppe S.M.; Slade D.E.; Chong K.T.; Hinshaw R.R.; Pagano P.J.; Markowitz M.; Ho D.D.; Mo H.; Gorman R.R.; Dueweke T.J.; Thaisrivongs S.; Tarpley W.G.; Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 1997,41(5),1058-1063","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1586\/14787210.3.1.9","volume":"3","author":"Kandula V.R.","year":"2005","unstructured":"Kandula V.R.; Khanlou H.; Farthing C.; Tipranavir: a novel second-generation nonpeptidic protease inhibitor. Expert Rev Anti Infect Ther 2005,3(1),9-21","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2165\/00003088-200645070-00003","volume":"45","author":"King J.R.","year":"2006","unstructured":"King J.R.; Acosta E.P.; Tipranavir: a novel nonpeptidic protease inhibitor of HIV. Clin Pharmacokinet 2006,45(7),665-682","journal-title":"Clin Pharmacokinet"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1128\/AAC.44.5.1328-1332.2000","volume":"44","author":"Rusconi S.","year":"2000","unstructured":"Rusconi S.; La Seta Catamancio S.; Citterio P.; Kurtagic S.; Violin M.; Balotta C.; Moroni M.; Galli M.; d\u2019Arminio-Monforte A.; Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother 2000,44(5),1328-1332","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1097\/00002030-200009080-00009","volume":"14","author":"Larder B.A.","year":"2000","unstructured":"Larder B.A.; Hertogs K.; Bloor S.; van den Eynde C.H.; DeCian W.; Wang Y.; Freimuth W.W.; Tarpley G.; Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 2000,14(13),1943-1948","journal-title":"AIDS"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/jac\/dkn429","volume":"63","author":"Mac\u00edas J.","year":"2009","unstructured":"Mac\u00edas J.; Orihuela F.; Rivero A.; Viciana P.; M\u00e1rquez M.; Portilla J.; R\u00edos M.J.; Mu\u00f1oz L.; Pasquau J.; Casta\u00f1o M.A.; Abdel-Kader L.; Pineda J.A.; Hepatic safety of tipranavir plus ritonavir (TPV\/r)-based antiretroviral combinations: Effect of hepatitis virus co-infection and pre-existing fibrosis. J Antimicrob Chemother 2009,63(1),178-183","journal-title":"J Antimicrob Chemother"},{"key":"ref=183","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1365-2516.2007.01447.x","volume":"14","author":"Arbuthnot C.","year":"2008","unstructured":"Arbuthnot C.; Wilde J.T.; Increased risk of bleeding with the use of tipranavir boosted with ritonavir in haemophilic patients. Haemophilia 2008,14(1),140-141","journal-title":"Haemophilia"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/S0140-6736(07)60499-1","volume":"369","author":"MacArthur R.D.","year":"2007","unstructured":"MacArthur R.D.; Darunavir: promising initial results. Lancet 2007,369(9568),1143-1144","journal-title":"Lancet"},{"key":"ref=185","unstructured":"FDA approves new HIV treatment for patients who do not respond to existing drugs. (Accessed 2006)","journal-title":"(Accessed 2006)"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1128\/AAC.47.10.3123-3129.2003","volume":"47","author":"Koh Y.","year":"2003","unstructured":"Koh Y.; Nakata H.; Maeda K.; Ogata H.; Bilcer G.; Devasamudram T.; Kincaid J.F.; Boross P.; Wang Y.F.; Tie Y.; Volarath P.; Gaddis L.; Harrison R.W.; Weber I.T.; Ghosh A.K.; Mitsuya H.; Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 2003,47(10),3123-3129","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1128\/JVI.76.3.1349-1358.2002","volume":"76","author":"Yoshimura K.","year":"2002","unstructured":"Yoshimura K.; Kato R.; Kavlick M.F.; Nguyen A.; Maroun V.; Maeda K.; Hussain K.A.; Ghosh A.K.; Gulnik S.V.; Erickson J.W.; Mitsuya H.; A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. J Virol 2002,76(3),1349-1358","journal-title":"J Virol"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1006\/jmbi.2000.4018","volume":"301","author":"Prabu-Jeyabalan M.","year":"2000","unstructured":"Prabu-Jeyabalan M.; Nalivaika E.; Schiffer C.A.; How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease. J Mol Biol 2000,301(5),1207-1220","journal-title":"J Mol Biol"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1747-0285.2008.00647.x","volume":"71","author":"Brower E.T.","year":"2008","unstructured":"Brower E.T.; Bacha U.M.; Kawasaki Y.; Freire E.; Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des 2008,71(4),298-305","journal-title":"Chem Biol Drug Des"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"12012","DOI":"10.1128\/JVI.78.21.12012-12021.2004","volume":"78","author":"King N.M.","year":"2004","unstructured":"King N.M.; Prabu-Jeyabalan M.; Nalivaika E.A.; Wigerinck P.; de B\u00e9thune M.P.; Schiffer C.A.; Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol 2004,78(21),12012-12021","journal-title":"J Virol"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"13845","DOI":"10.1128\/JVI.01184-07","volume":"81","author":"Dierynck I.","year":"2007","unstructured":"Dierynck I.; De Wit M.; Gustin E.; Keuleers I.; Vandersmissen J.; Hallenberger S.; Hertogs K.; Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol 2007,81(24),13845-13851","journal-title":"J Virol"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1747-0285.2007.00514.x","volume":"69","author":"Chellappan S.","year":"2007","unstructured":"Chellappan S.; Kiran Kumar Reddy G.S.; Ali A.; Nalam M.N.; Anjum S.G.; Cao H.; Kairys V.; Fernandes M.X.; Altman M.D.; Tidor B.; Rana T.M.; Schiffer C.A.; Gilson M.K.; Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis. Chem Biol Drug Des 2007,69(5),298-313","journal-title":"Chem Biol Drug Des"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jmb.2006.08.007","volume":"363","author":"Kovalevsky A.Y.","year":"2006","unstructured":"Kovalevsky A.Y.; Liu F.; Leshchenko S.; Ghosh A.K.; Louis J.M.; Harrison R.W.; Weber I.T.; Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114. J Mol Biol 2006,363(1),161-173","journal-title":"J Mol Biol"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"6599","DOI":"10.1021\/jm800283k","volume":"51","author":"Kovalevsky A.Y.","year":"2008","unstructured":"Kovalevsky A.Y.; Ghosh A.K.; Weber I.T.; Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir. J Med Chem 2008,51(20),6599-6603","journal-title":"J Med Chem"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-013-0159-3","volume":"74","author":"Deeks E.D.","year":"2014","unstructured":"Deeks E.D.; Darunavir: A review of its use in the management of HIV-1 infection. Drugs 2014,74(1),99-125","journal-title":"Drugs"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/QAI.0b013e3181359cfb","volume":"46","author":"Molina J.M.","year":"2007","unstructured":"Molina J.M.; Cohen C.; Katlama C.; Grinsztejn B.; Timerman A.; Pedro, Rde.J.; Vangeneugden, T.; Miralles, D.; Meyer, S.D.; Parys, W.; Lefebvre, E. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr 2007,46(1),24-31","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=197","unstructured":"European commission approves symtuza\u00ae for the treatment of HIV-1 in adults and adolescents in europe. Janssen press statement (Accessed 2017)."},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1097\/QAD.0000000000001817","volume":"32","author":"Orkin C.","year":"2017","unstructured":"Orkin C.; Week 48 results of AMBER: A phase 3, randomised, doubleblind trial in antiretroviral treatment (ART)-naive HIV-1-infected adults to evaluate the efficacy and safety of the once-daily, single-tablet regimen (STR) of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide (D\/C\/F\/TAF) versus darunavir\/cobicistat (DRV\/c) plus emtricitabine\/tenofovir disoproxil fumarate (FTC\/TDF). AIDS 2017,32(11),1431-1442","journal-title":"AIDS"},{"key":"ref=199","author":"Link J.O.","year":"2017","unstructured":"Link J.O.; Katto D.; Moore M.; Mulato A.; Murray B.; Mwangi J.; Shapiro N.D.; Stepan G.; Wang Y.; Yang Z-Y.; In: Abstract 433, Novel HIV PI with high resistance barrier and potential for unboosted QD oral dosing, The Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, USA, February 13\u2013 16, 2017; Gilead Scis, Inc: Foster City, CA, USA, 2017"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.1128\/AAC.00149-07","volume":"51","author":"Dandache S.","year":"2007","unstructured":"Dandache S.; S\u00e9vigny G.; Yelle J.; Stranix B.R.; Parkin N.; Schapiro J.M.; Wainberg M.A.; Wu J.J.; In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2007,51(11),4036-4043","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"9512","DOI":"10.1128\/JVI.00799-07","volume":"81","author":"Nalam M.N.","year":"2007","unstructured":"Nalam M.N.; Peeters A.; Jonckers T.H.; Dierynck I.; Schiffer C.A.; Crystal structure of lysine sulfonamide inhibitor reveals the displacement of the conserved flap water molecule in human immunodeficiency virus type 1 protease. J Virol 2007,81(17),9512-9518","journal-title":"J Virol"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/jac\/dks342","volume":"68","author":"Asahchop E.L.","year":"2013","unstructured":"Asahchop E.L.; Oliveira M.; Quashie P.K.; Moisi D.; Martinez-Cajas J.L.; Brenner B.G.; Tremblay C.L.; Wainberg M.A.; In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor. J Antimicrob Chemother 2013,68(1),105-112","journal-title":"J Antimicrob Chemother"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1002\/jmv.21329","volume":"80","author":"Dandache S.","year":"2008","unstructured":"Dandache S.; Coburn C.A.; Oliveira M.; Allison T.J.; Holloway M.K.; Wu J.J.; Stranix B.R.; Panchal C.; Wainberg M.A.; Vacca J.P.; PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: An in vitro selection study. J Med Virol 2008,80(12),2053-2063","journal-title":"J Med Virol"},{"key":"ref=204","year":"2017","unstructured":"Study of the Safety. Tolerability and pharmacokinetics of TMB- 607 in HIV-negative volunteers. ClinicalTrials.gov, (Available at:2017"},{"key":"ref=205","year":"2013","unstructured":"Pharmacokinetics, safety"},{"key":"ref=206","author":"Holland A.","unstructured":"Holland A.; Corp C.; Wynne B.; Ruff D.; Guttendorf R.; A first in human study evaluating the safety, tolerability, and pharmacokinetics (PK) of SPI-256, a novel HIV protease inhibitor (PI), administered alone and in combination with ritonavir (RTV) in healthy adult subjects. Poster presented at the 48th Annual ICAAC\/46th Annual IDSA Meeting, 2008, October 25\u201328; 2008; Washington, DC. (Accessed on March 4, 2019 at"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1097\/COH.0b013e328313911d","volume":"3","author":"Gulnik S.V.","year":"2008","unstructured":"Gulnik S.V.; Eissenstat M.; Approaches to the design of HIV protease inhibitors with improved resistance profiles. Curr Opin HIV AIDS 2008,3(6),633-641","journal-title":"Curr Opin HIV AIDS"},{"key":"ref=208","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/401965","volume":"2012","author":"Hartman T.L.","year":"2012","unstructured":"Hartman T.L.; Buckheit R.W.; The continuing evolution of HIV-1 therapy: Identification and development of novel antiretroviral agents targeting viral and cellular targets. Mol Biol Int 2012,2012","journal-title":"Mol Biol Int"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jmb.2006.07.073","volume":"363","author":"Cihlar T.","year":"2006","unstructured":"Cihlar T.; He G.X.; Liu X.; Chen J.M.; Hatada M.; Swaminathan S.; McDermott M.J.; Yang Z.Y.; Mulato A.S.; Chen X.; Leavitt S.A.; Stray K.M.; Lee W.A.; Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring. J Mol Biol 2006,363(3),635-647","journal-title":"J Mol Biol"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1128\/AAC.01183-10","volume":"55","author":"Callebaut C.","year":"2011","unstructured":"Callebaut C.; Stray K.; Tsai L.; Williams M.; Yang Z.Y.; Cannizzaro C.; Leavitt S.A.; Liu X.; Wang K.; Murray B.P.; Mulato A.; Hatada M.; Priskich T.; Parkin N.; Swaminathan S.; Lee W.; He G.X.; Xu L.; Cihlar T.; In vitro characterization of GS-8374, a novel phosphonate-containing inhibitor of HIV-1 protease with a favorable resistance profile. Antimicrob Agents Chemother 2011,55(4),1366-1376","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"30433","DOI":"10.1074\/jbc.R800035200","volume":"283","author":"L\u00f3pez-Ot\u00edn C.","year":"2008","unstructured":"L\u00f3pez-Ot\u00edn C.; Bond J.S.; Proteases: multifunctional enzymes in life and disease. J Biol Chem 2008,283(45),30433-30437","journal-title":"J Biol Chem"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/nrd3053","volume":"9","author":"Drag M.","year":"2010","unstructured":"Drag M.; Salvesen G.S.; Emerging principles in protease-based drug discovery. Nat Rev Drug Discov 2010,9(9),690-701","journal-title":"Nat Rev Drug Discov"},{"key":"ref=213","first-page":"95","volume":"7","author":"Lv Z.","year":"2015","unstructured":"Lv Z.; Chu Y.; Wang Y.; HIV protease inhibitors: A review of molecular selectivity and toxicity. HIV AIDS (Auckl) 2015,7,95-104","journal-title":"HIV AIDS (Auckl)"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1039\/b208248a","volume":"1","author":"Brik A.","year":"2003","unstructured":"Brik A.; Wong C.H.; HIV-1 protease: Mechanism and drug discovery. Org Biomol Chem 2003,1(1),5-14","journal-title":"Org Biomol Chem"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.str.2009.10.008","volume":"17","author":"Chaudhury S.","year":"2009","unstructured":"Chaudhury S.; Gray J.J.; Identification of structural mechanisms of HIV-1 protease specificity using computational peptide docking: implications for drug resistance. Structure 2009,17(12),1636-1648","journal-title":"Structure"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2165\/00003088-200443050-00003","volume":"43","author":"King J.R.","year":"2004","unstructured":"King J.R.; Wynn H.; Brundage R.; Acosta E.P.; Pharmacokinetic enhancement of protease inhibitor therapy. Clin Pharmacokinet 2004,43(5),291-310","journal-title":"Clin Pharmacokinet"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1056\/NEJM199804303381808","volume":"338","author":"Flexner C.","year":"1998","unstructured":"Flexner C.; HIV-protease inhibitors. N Engl J Med 1998,338(18),1281-1292","journal-title":"N Engl J Med"},{"key":"ref=218","doi-asserted-by":"publisher","DOI":"10.1036\/0071422803","author":"Flexner C.W.","year":"2011","unstructured":"Flexner C.W.; Antiretroviral agents and treatment of HIV infection Goodman 2011","journal-title":"Goodman"},{"key":"ref=219","year":"2018","unstructured":"Lexi-Comp, Inc. Drug information handbook. ( 27th Ed.), Lexi-Comp, Hudson, OH., Wolters Kluwer, 2018"},{"key":"ref=220","author":"McEvoy G.K.","year":"2015","unstructured":"McEvoy G.K.; SE; Kester, L; Litvak, K; Miller, J; Welsh, OH AHFS 2015 Drug Information 2015","journal-title":"SE; Kester, L; Litvak, K; Miller, J; Welsh, OH AHFS 2015 Drug Information"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2165\/00003088-199834030-00002","volume":"34","author":"Vella S.","year":"1998","unstructured":"Vella S.; Floridia M.; Saquinavir. Clinical pharmacology and efficacy. Clin Pharmacokinet 1998,34(3),189-201","journal-title":"Clin Pharmacokinet"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1517\/14656566.2.2.303","volume":"2","author":"Kravcik S.","year":"2001","unstructured":"Kravcik S.; Pharmacology and clinical experience with saquinavir. Expert Opin Pharmacother 2001,2(2),303-315","journal-title":"Expert Opin Pharmacother"},{"key":"ref=223","year":"2019","unstructured":"AIDSInfo. 2019. (Avaiable at: 2019"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.2174\/138920012802850119","volume":"13","author":"Zha W.","year":"2012","unstructured":"Zha W.; Zha B.S.; Zhou F.; Zhou H.; Wang G.; The cellular pharmacokinetics of HIV protease inhibitors: current knowledge and future perspectives. Curr Drug Metab 2012,13(8),1174-1183","journal-title":"Curr Drug Metab"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2165\/00003088-199835040-00002","volume":"35","author":"Hsu A.","year":"1998","unstructured":"Hsu A.; Granneman G.R.; Bertz R.J.; Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998,35(4),275-291","journal-title":"Clin Pharmacokinet"},{"key":"ref=226","unstructured":"AIDSInfo. (Accessed 2019)."},{"key":"ref=227","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1128\/AAC.48.9.3226-3232.2004","volume":"48","author":"Csajka C.","year":"2004","unstructured":"Csajka C.; Marzolini C.; Fattinger K.; D\u00e9costerd L.A.; Telenti A.; Biollaz J.; Buclin T.; Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 2004,48(9),3226-3232","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1023\/A:1008629608556","volume":"19","author":"Hoetelmans R.M.","year":"1997","unstructured":"Hoetelmans R.M.; Meenhorst P.L.; Mulder J.W.; Burger D.M.; Koks C.H.; Beijnen J.H.; Clinical pharmacology of HIV protease inhibitors: Focus on saquinavir, indinavir, and ritonavir. Pharm World Sci 1997,19(4),159-175","journal-title":"Pharm World Sci"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1345\/aph.18089","volume":"33","author":"Pai V.B.","year":"1999","unstructured":"Pai V.B.; Nahata M.C.; Nelfinavir mesylate: A protease inhibitor. Ann Pharmacother 1999,33(3),325-339","journal-title":"Ann Pharmacother"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1345\/aph.10423","volume":"36","author":"Sadler B.M.","year":"2002","unstructured":"Sadler B.M.; Stein D.S.; Clinical pharmacology and pharmacokinetics of amprenavir. Ann Pharmacother 2002,36(1),102-118","journal-title":"Ann Pharmacother"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1517\/17425250903321514","volume":"5","author":"Bentu\u00e9-Ferrer D.","year":"2009","unstructured":"Bentu\u00e9-Ferrer D.; Arvieux C.; Tribut O.; Ruffault A.; Bellissant E.; Clinical pharmacology, efficacy and safety of atazanavir: a review. Expert Opin Drug Metab Toxicol 2009,5(11),1455-1468","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=232","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1128\/AAC.00098-06","volume":"50","author":"Colombo S.","year":"2006","unstructured":"Colombo S.; Buclin T.; Cavassini M.; D\u00e9costerd L.A.; Telenti A.; Biollaz J.; Csajka C.; Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 2006,50(11),3801-3808","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=233","unstructured":"AIDSInfo. 2019. (Available at:"},{"key":"ref=234","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2165\/00003088-200645020-00002","volume":"45","author":"Wire M.B.","year":"2006","unstructured":"Wire M.B.; Shelton M.J.; Studenberg S.; Fosamprenavir: Clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet 2006,45(2),137-168","journal-title":"Clin Pharmacokinet"},{"key":"ref=235","unstructured":"AIDSInfo."},{"key":"ref=236","unstructured":"AIDSInfo. (Accessed 2019)."},{"key":"ref=237","doi-asserted-by":"publisher","first-page":"739","DOI":"10.2165\/00003088-200746090-00002","volume":"46","author":"Rittweger M.","year":"2007","unstructured":"Rittweger M.; Arast\u00e9h K.; Clinical pharmacokinetics of darunavir. Clin Pharmacokinet 2007,46(9),739-756","journal-title":"Clin Pharmacokinet"},{"key":"ref=238","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000339862","volume":"90","author":"Ruela Corr\u00eaa J.C.","year":"2012","unstructured":"Ruela Corr\u00eaa J.C.; D\u2019Arcy D.M.; dos Reis Serra C.H.; Nunes Salgado H.R.; Darunavir: A critical review of its properties, use and drug interactions. Pharmacology 2012,90(1-2),102-109","journal-title":"Pharmacology"},{"key":"ref=239","unstructured":"AIDSInfo. (Accessed 2019)."},{"key":"ref=240","unstructured":"Drug-Drug Interactions. Drug-Drug Interactions: Drug Interactions between Protease Inhibitors and Other Drugs. (Accessed 2018)."},{"key":"ref=241","author":"Okulicz J.F.","unstructured":"Okulicz J.F.; Common Drug Interactions with Protease Inhibitors (Accessed on 2019).","journal-title":"Common Drug Interactions with Protease Inhibitors"},{"key":"ref=242","unstructured":"High-Alert Medications in Community\/Ambulatory Settings. In: Institute for Safe Medication Practices. (Accessed 2011)."},{"key":"ref=243","author":"Levinson W.","year":"2014","unstructured":"Levinson W.; Antiviral drugs: Review of medical microbilogy and immunology. McGraw-Hill's Medicine and Health 13th ed; New York, NY,2014","journal-title":"McGraw-Hill's Medicine and Health"},{"key":"ref=244","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1006\/viro.1998.9383","volume":"250","author":"Molla A.","year":"1998","unstructured":"Molla A.; Vasavanonda S.; Kumar G.; Sham H.L.; Johnson M.; Grabowski B.; Denissen J.F.; Kohlbrenner W.; Plattner J.J.; Leonard J.M.; Norbeck D.W.; Kempf D.J.; Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 1998,250(2),255-262","journal-title":"Virology"},{"key":"ref=245","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1097\/QAI.0b013e318186519c","volume":"49","author":"Kotler D.P.","year":"2008","unstructured":"Kotler D.P.; HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J Acquir Immune Defic Syndr 2008,49(Suppl. 2),S79-S85","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=246","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1097\/QAI.0b013e31818651e6","volume":"49","author":"Tebas P.","year":"2008","unstructured":"Tebas P.; Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options. J Acquir Immune Defic Syndr 2008,49(Suppl. 2),S86-S92","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=247","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1056\/NEJMra041811","volume":"352","author":"Grinspoon S.","year":"2005","unstructured":"Grinspoon S.; Carr A.; Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005,352(1),48-62","journal-title":"N Engl J Med"},{"key":"ref=248","doi-asserted-by":"publisher","first-page":"37514","DOI":"10.1074\/jbc.M104557200","volume":"276","author":"Riddle T.M.","year":"2001","unstructured":"Riddle T.M.; Kuhel D.G.; Woollett L.A.; Fichtenbaum C.J.; Hui D.Y.; HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001,276(40),37514-37519","journal-title":"J Biol Chem"},{"key":"ref=249","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1097\/QAD.0b013e328315a7a5","volume":"22","author":"Carr A.","year":"2008","unstructured":"Carr A.; Ritzhaupt A.; Zhang W.; Zajdenverg R.; Workman C.; Gatell J.M.; Cahn P.; Chaves R.; Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults. AIDS 2008,22(17),2313-2321","journal-title":"AIDS"},{"key":"ref=250","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s40265-013-0108-1","volume":"73","author":"Guaraldi G.","year":"2013","unstructured":"Guaraldi G.; Stentarelli C.; Zona S.; Santoro A.; HIV-associated lipodystrophy: impact of antiretroviral therapy. Drugs 2013,73(13),1431-1450","journal-title":"Drugs"},{"key":"ref=251","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063623","volume":"8","author":"de Waal R.","year":"2013","unstructured":"de Waal R.; Cohen K.; Maartens G.; Systematic review of antiretroviral-associated lipodystrophy: Lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS One 2013,8(5)","journal-title":"PLoS One"},{"key":"ref=252","unstructured":"Adverse Effects of Antiretroviral Agents. (Accessed 2018)."},{"key":"ref=253","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","volume":"72","author":"Tang M.W.","year":"2012","unstructured":"Tang M.W.; Shafer R.W.; HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs 2012,72(9),e1-e25","journal-title":"Drugs"},{"key":"ref=254","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1089\/108729104323038874","volume":"18","author":"Kozal M.","year":"2004","unstructured":"Kozal M.; Cross-resistance patterns among HIV protease inhibitors. AIDS Patient Care STDS 2004,18(4),199-208","journal-title":"AIDS Patient Care STDS"},{"key":"ref=255","first-page":"132","volume":"24","author":"Wensing A.M.","year":"2017","unstructured":"Wensing A.M.; Calvez V.; G\u00fcnthard H.F.; Johnson V.A.; Paredes R.; Pillay D.; Shafer R.W.; Richman D.D.; 2017 Update of the drug resistance mutations in HIV-1. Top Antivir Med 2017,24(4),132-133","journal-title":"Top Antivir Med"},{"key":"ref=256","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1086\/503914","volume":"42","author":"Liu T.F.","year":"2006","unstructured":"Liu T.F.; Shafer R.W.; Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006,42(11),1608-1618","journal-title":"Clin Infect Dis"},{"key":"ref=257","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/QAD.0b013e328011e691","volume":"21","author":"Shafer R.W.","year":"2007","unstructured":"Shafer R.W.; Rhee S.Y.; Pillay D.; Miller V.; Sandstrom P.; Schapiro J.M.; Kuritzkes D.R.; Bennett D.; HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007,21(2),215-223","journal-title":"AIDS"},{"key":"ref=258","author":"P.I. Resistance Notes","unstructured":"P.I. Resistance Notes; In:HIV Drug Resistance Database (Accessed 2019).","journal-title":"In:HIV Drug Resistance Database"},{"key":"ref=259","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1086\/386291","volume":"189","author":"Colonno R.","year":"2004","unstructured":"Colonno R.; Rose R.; McLaren C.; Thiry A.; Parkin N.; Friborg J.; Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis 2004,189(10),1802-1810","journal-title":"J Infect Dis"},{"key":"ref=260","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jcv.2008.03.023","volume":"42","author":"Sista P.","year":"2008","unstructured":"Sista P.; Wasikowski B.; Lecocq P.; Pattery T.; Bacheler L.; The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contexts. J Clin Virol 2008,42(4),405-408","journal-title":"J Clin Virol"},{"key":"ref=261","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1128\/AAC.49.9.3816-3824.2005","volume":"49","author":"Weinheimer S.","year":"2005","unstructured":"Weinheimer S.; Discotto L.; Friborg J.; Yang H.; Colonno R.; Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones. Antimicrob Agents Chemother 2005,49(9),3816-3824","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=262","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.1128\/AAC.49.9.3825-3832.2005","volume":"49","author":"Yanchunas J.","year":"2005","unstructured":"Yanchunas J.; Langley D.R.; Tao L.; Rose R.E.; Friborg J.; Colonno R.J.; Doyle M.L.; Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors. Antimicrob Agents Chemother 2005,49(9),3825-3832","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=263","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1128\/JVI.74.9.4414-4419.2000","volume":"74","author":"Ziermann R.","year":"2000","unstructured":"Ziermann R.; Limoli K.; Das K.; Arnold E.; Petropoulos C.J.; Parkin N.T.; A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J Virol 2000,74(9),4414-4419","journal-title":"J Virol"},{"key":"ref=264","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/jac\/dkg392","volume":"52","author":"Paulsen D.","year":"2003","unstructured":"Paulsen D.; Elston R.; Snowden W.; Tisdale M.; Ross L.; Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects. J Antimicrob Chemother 2003,52(3),319-323","journal-title":"J Antimicrob Chemother"},{"key":"ref=265","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1097\/QAD.0b013e32832cbcec","volume":"23","author":"De Meyer S.","year":"2009","unstructured":"De Meyer S.; Lathouwers E.; Dierynck I.; De Paepe E.; Van Baelen B.; Vangeneugden T.; Spinosa-Guzman S.; Lefebvre E.; Picchio G.; de B\u00e9thune M.P.; Characterization of virologic failure patients on darunavir\/ritonavir in treatment-experienced patients. AIDS 2009,23(14),1829-1840","journal-title":"AIDS"},{"key":"ref=266","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1089\/aid.2007.0173","volume":"24","author":"de Meyer S.","year":"2008","unstructured":"de Meyer S.; Vangeneugden T.; van Baelen B.; de Paepe E.; van Marck H.; Picchio G.; Lefebvre E.; de B\u00e9thune M.P.; Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 2008,24(3),379-388","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref=267","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1097\/QAD.0b013e328307f24a","volume":"22","author":"Delaugerre C.","year":"2008","unstructured":"Delaugerre C.; Pavie J.; Palmer P.; Ghosn J.; Blanche S.; Roudiere L.; Dominguez S.; Mortier E.; Molina J.M.; de Truchis P.; Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen. AIDS 2008,22(14),1809-1813","journal-title":"AIDS"},{"key":"ref=268","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s15010-011-0237-y","volume":"40","author":"Sterrantino G.","year":"2012","unstructured":"Sterrantino G.; Zaccarelli M.; Colao G.; Baldanti F.; Di Giambenedetto S.; Carli T.; Maggiolo F.; Zazzi M.; Group A.D.S.; Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis. Infection 2012,40(3),311-318","journal-title":"Infection"},{"key":"ref=269","doi-asserted-by":"publisher","first-page":"4903","DOI":"10.1128\/AAC.00906-10","volume":"54","author":"Young T.P.","year":"2010","unstructured":"Young T.P.; Parkin N.T.; Stawiski E.; Pilot-Matias T.; Trinh R.; Kempf D.J.; Norton M.; Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease. Antimicrob Agents Chemother 2010,54(11),4903-4906","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=270","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1086\/650732","volume":"50","author":"Llibre J.M.","year":"2010","unstructured":"Llibre J.M.; Schapiro J.M.; Clotet B.; Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure. Clin Infect Dis 2010,50(6),872-881","journal-title":"Clin Infect Dis"},{"key":"ref=271","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1128\/AAC.00909-07","volume":"52","author":"Lambert-Niclot S.","year":"2008","unstructured":"Lambert-Niclot S.; Flandre P.; Canestri A.; Peytavin G.; Blanc C.; Agher R.; Souli\u00e9 C.; Wirden M.; Katlama C.; Calvez V.; Marcelin A.G.; Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir. Antimicrob Agents Chemother 2008,52(2),491-496","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=272","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1128\/AAC.46.3.731-738.2002","volume":"46","author":"Maguire M.","year":"2002","unstructured":"Maguire M.; Shortino D.; Klein A.; Harris W.; Manohitharajah V.; Tisdale M.; Elston R.; Yeo J.; Randall S.; Xu F.; Parker H.; May J.; Snowden W.; Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob Agents Chemother 2002,46(3),731-738","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=273","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jmv.20140","volume":"74","author":"Marcelin A.G.","year":"2004","unstructured":"Marcelin A.G.; Affolabi D.; Lamotte C.; Mohand H.A.; Delaugerre C.; Wirden M.; Voujon D.; Bossi P.; Ktorza N.; Bricaire F.; Costagliola D.; Katlama C.; Peytavin G.; Calvez V.; Resistance profiles observed in virological failures after 24 weeks of amprenavir\/ritonavir containing regimen in protease inhibitor experienced patients. J Med Virol 2004,74(1),16-20","journal-title":"J Med Virol"},{"key":"ref=274","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1128\/AAC.00514-08","volume":"52","author":"Marcelin A.G.","year":"2008","unstructured":"Marcelin A.G.; Flandre P.; Molina J.M.; Katlama C.; Yeni P.; Raffi F.; Antoun Z.; Ait-Khaled M.; Calvez V.; Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials. Antimicrob Agents Chemother 2008,52(12),4251-4257","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=275","doi-asserted-by":"crossref","first-page":"8270","DOI":"10.1128\/JVI.70.12.8270-8276.1996","volume":"70","author":"Condra J.H.","year":"1996","unstructured":"Condra J.H.; Holder D.J.; Schleif W.A.; Blahy O.M.; Danovich R.M.; Gabryelski L.J.; Graham D.J.; Laird D.; Quintero J.C.; Rhodes A.; Robbins H.L.; Roth E.; Shivaprakash M.; Yang T.; Chodakewitz J.A.; Deutsch P.J.; Leavitt R.Y.; Massari F.E.; Mellors J.W.; Squires K.E.; Steigbigel R.T.; Teppler H.; Emini E.A.; Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996,70(12),8270-8276","journal-title":"J Virol"},{"key":"ref=276","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1086\/315429","volume":"181","author":"B\u00e9lec L.","year":"2000","unstructured":"B\u00e9lec L.; Piketty C.; Si-Mohamed A.; Goujon C.; Hallouin M.C.; Cotigny S.; Weiss L.; Kazatchkine M.D.; High levels of drug-resistant human immunodeficiency virus variants in patients exhibiting increasing CD4+ T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy. J Infect Dis 2000,181(5),1808-1812","journal-title":"J Infect Dis"},{"key":"ref=277","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/jac\/dkr569","volume":"67","author":"Barber T.J.","year":"2012","unstructured":"Barber T.J.; Harrison L.; Asboe D.; Williams I.; Kirk S.; Gilson R.; Bansi L.; Pillay D.; Dunn D.; Database U.H.D.R.; Committees U.K.C.H.C.S.S.; Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir\/ritonavir as their first protease inhibitor. J Antimicrob Chemother 2012,67(4),995-1000","journal-title":"J Antimicrob Chemother"},{"key":"ref=278","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1128\/JVI.79.6.3329-3338.2005","volume":"79","author":"Mo H.","year":"2005","unstructured":"Mo H.; King M.S.; King K.; Molla A.; Brun S.; Kempf D.J.; Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: Mutation patterns and baseline correlates. J Virol 2005,79(6),3329-3338","journal-title":"J Virol"},{"key":"ref=279","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1097\/01.aids.0000222084.44411.cc","volume":"20","author":"de Mendoza C.","year":"2006","unstructured":"de Mendoza C.; Valer L.; Bacheler L.; Pattery T.; Corral A.; Soriano V.; Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance. AIDS 2006,20(7),1071-1074","journal-title":"AIDS"},{"key":"ref=280","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/nar\/gkg100","volume":"31","author":"Rhee S.Y.","year":"2003","unstructured":"Rhee S.Y.; Gonzales M.J.; Kantor R.; Betts B.J.; Ravela J.; Shafer R.W.; Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003,31(1),298-303","journal-title":"Nucleic Acids Res"},{"key":"ref=281","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1086\/315726","volume":"182","author":"Atkinson B.","year":"2000","unstructured":"Atkinson B.; Isaacson J.; Knowles M.; Mazabel E.; Patick A.K.; Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine. J Infect Dis 2000,182(2),420-427","journal-title":"J Infect Dis"},{"key":"ref=282","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1128\/AAC.42.10.2637","volume":"42","author":"Patick A.K.","year":"1998","unstructured":"Patick A.K.; Duran M.; Cao Y.; Shugarts D.; Keller M.R.; Mazabel E.; Knowles M.; Chapman S.; Kuritzkes D.R.; Markowitz M.; Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother 1998,42(10),2637-2644","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=283","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0166-3542(03)00107-4","volume":"59","author":"Mo H.","year":"2003","unstructured":"Mo H.; Lu L.; Dekhtyar T.; Stewart K.D.; Sun E.; Kempf D.J.; Molla A.; Characterization of resistant HIV variants generated by in vitro passage with lopinavir\/ritonavir. Antiviral Res 2003,59(3),173-180","journal-title":"Antiviral Res"},{"key":"ref=284","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1128\/AAC.46.4.1086-1092.2002","volume":"46","author":"Kantor R.","year":"2002","unstructured":"Kantor R.; Fessel W.J.; Zolopa A.R.; Israelski D.; Shulman N.; Montoya J.G.; Harbour M.; Schapiro J.M.; Shafer R.W.; Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. Antimicrob Agents Chemother 2002,46(4),1086-1092","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=285","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1089\/aid.2006.22.1300","volume":"22","author":"Mitsuya Y.","year":"2006","unstructured":"Mitsuya Y.; Winters M.A.; Fessel W.J.; Rhee S.Y.; Hurley L.; Horberg M.; Schiffer C.A.; Zolopa A.R.; Shafer R.W.; N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. AIDS Res Hum Retroviruses 2006,22(12),1300-1305","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref=286","doi-asserted-by":"publisher","first-page":"10794","DOI":"10.1128\/JVI.00712-06","volume":"80","author":"Baxter J.D.","year":"2006","unstructured":"Baxter J.D.; Schapiro J.M.; Boucher C.A.; Kohlbrenner V.M.; Hall D.B.; Scherer J.R.; Mayers D.L.; Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 2006,80(21),10794-10801","journal-title":"J Virol"},{"key":"ref=287","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3851\/IMP1670","volume":"15","author":"Schapiro J.M.","year":"2010","unstructured":"Schapiro J.M.; Scherer J.; Boucher C.A.; Baxter J.D.; Tilke C.; Perno C.F.; Maggiolo F.; Santoro M.M.; Hall D.B.; Improving the prediction of virological response to tipranavir: The development and validation of a tipranavir-weighted mutation score. Antivir Ther (Lond) 2010,15(7),1011-1019","journal-title":"Antivir Ther (Lond)"},{"key":"ref=288","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1128\/AAC.00574-10","volume":"54","author":"Rhee S.Y.","year":"2010","unstructured":"Rhee S.Y.; Taylor J.; Fessel W.J.; Kaufman D.; Towner W.; Troia P.; Ruane P.; Hellinger J.; Shirvani V.; Zolopa A.; Shafer R.W.; HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother 2010,54(10),4253-4261","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=289","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1089\/aid.2011.0242","volume":"28","author":"Bethell R.","year":"2012","unstructured":"Bethell R.; Scherer J.; Witvrouw M.; Paquet A.; Coakley E.; Hall D.; Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes. AIDS Res Hum Retroviruses 2012,28(9),1019-1024","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref=290","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1128\/AAC.00592-09","volume":"53","author":"Shahriar R.","year":"2009","unstructured":"Shahriar R.; Rhee S.Y.; Liu T.F.; Fessel W.J.; Scarsella A.; Towner W.; Holmes S.P.; Zolopa A.R.; Shafer R.W.; Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations. Antimicrob Agents Chemother 2009,53(11),4869-4878","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=291","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1089\/apc.2007.0099","volume":"22","author":"Kim R.","year":"2008","unstructured":"Kim R.; Baxter J.D.; Protease inhibitor resistance update: where are we now? AIDS Patient Care STDS 2008,22(4),267-277","journal-title":"AIDS Patient Care STDS"},{"key":"ref=292","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1097\/00002030-199910220-00008","volume":"13","author":"Race E.","year":"1999","unstructured":"Race E.; Dam E.; Obry V.; Paulous S.; Clavel F.; Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS 1999,13(15),2061-2068","journal-title":"AIDS"},{"key":"ref=293","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1128\/JVI.70.6.3763-3769.1996","volume":"70","author":"Doyon L.","year":"1996","unstructured":"Doyon L.; Croteau G.; Thibeault D.; Poulin F.; Pilote L.; Lamarre D.; Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 1996,70(6),3763-3769","journal-title":"J Virol"},{"key":"ref=294","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1128\/JVI.71.9.6662-6670.1997","volume":"71","author":"Zhang Y.M.","year":"1997","unstructured":"Zhang Y.M.; Imamichi H.; Imamichi T.; Lane H.C.; Falloon J.; Vasudevachari M.B.; Salzman N.P.; Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 1997,71(9),6662-6670","journal-title":"J Virol"},{"key":"ref=295","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S1054-3589(00)49023-X","volume":"49","author":"Clavel F.","year":"2000","unstructured":"Clavel F.; Race E.; Mammano F.; HIV drug resistance and viral fitness. Adv Pharmacol 2000,49,41-66","journal-title":"Adv Pharmacol"},{"key":"ref=296","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/00001432-200102000-00005","volume":"14","author":"Nijhuis M.","year":"2001","unstructured":"Nijhuis M.; Deeks S.; Boucher C.; Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis 2001,14(1),23-28","journal-title":"Curr Opin Infect Dis"},{"key":"ref=297","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1097\/00126334-200103011-00005","volume":"26","author":"Miller V.","year":"2001","unstructured":"Miller V.; International perspectives on antiretroviral resistance. Resistance to protease inhibitors. J Acquir Immune Defic Syndr 2001,26(Suppl. 1),S34-S50","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=298","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/374569a0","volume":"374","author":"Condra J.H.","year":"1995","unstructured":"Condra J.H.; Schleif W.A.; Blahy O.M.; Gabryelski L.J.; Graham D.J.; Quintero J.C.; Rhodes A.; Robbins H.L.; Roth E.; Shivaprakash M.; In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995,374(6522),569-571","journal-title":"Nature"},{"key":"ref=299","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/nm0796-760","volume":"2","author":"Molla A.","year":"1996","unstructured":"Molla A.; Korneyeva M.; Gao Q.; Vasavanonda S.; Schipper P.J.; Mo H.M.; Markowitz M.; Chernyavskiy T.; Niu P.; Lyons N.; Hsu A.; Granneman G.R.; Ho D.D.; Boucher C.A.; Leonard J.M.; Norbeck D.W.; Kempf D.J.; Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996,2(7),760-766","journal-title":"Nat Med"},{"key":"ref=300","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/BF02253518","volume":"6","author":"Berkhout B.","year":"1999","unstructured":"Berkhout B.; HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness. J Biomed Sci 1999,6(5),298-305","journal-title":"J Biomed Sci"},{"key":"ref=301","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s13181-015-0465-0","volume":"11","author":"Stolbach A.","year":"2015","unstructured":"Stolbach A.; Paziana K.; Heverling H.; Pham P.; A Review of the toxicity of HIV medications II: Interactions with drugs and complementary and alternative medicine products. J Med Toxicol 2015,11(3),326-341","journal-title":"J Med Toxicol"},{"key":"ref=302","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/jac\/dkp152","volume":"64","author":"Seden K.","year":"2009","unstructured":"Seden K.; Back D.; Khoo S.; Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable. J Antimicrob Chemother 2009,64(1),5-8","journal-title":"J Antimicrob Chemother"},{"key":"ref=303","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.tim.2016.03.010","volume":"24","author":"Kurt Yilmaz N.","year":"2016","unstructured":"Kurt Yilmaz N.; Swanstrom R.; Schiffer C.A.; Improving viral protease inhibitors to counter drug resistance. Trends Microbiol 2016,24(7),547-557","journal-title":"Trends Microbiol"},{"key":"ref=304","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3390\/v1031110","volume":"1","author":"Weber I.T.","year":"2009","unstructured":"Weber I.T.; Agniswamy J.; HIV-1 Protease: Structural Perspectives on Drug Resistance. Viruses 2009,1(3),1110-1136","journal-title":"Viruses"},{"key":"ref=305","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.4155\/fmc.15.44","volume":"7","author":"Weber I.T.","year":"2015","unstructured":"Weber I.T.; Kneller D.W.; Wong-Sam A.; Highly resistant HIV-1 proteases and strategies for their inhibition. Future Med Chem 2015,7(8),1023-1038","journal-title":"Future Med Chem"},{"key":"ref=306","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/anie.201102762","volume":"51","author":"Ghosh A.K.","year":"2012","unstructured":"Ghosh A.K.; Anderson D.D.; Weber I.T.; Mitsuya H.; Enhancing protein backbone binding-a fruitful concept for combating drug-resistant HIV. Angew Chem Int Ed Engl 2012,51(8),1778-1802","journal-title":"Angew Chem Int Ed Engl"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/172800","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T07:02:06Z","timestamp":1721458926000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/172800\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,9]]},"references-count":306,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2019,10,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026619666190619115243","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-04-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}